| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2026―Jun―26 |
Covid-19 vaccine/Cyclophosphamide/Dexamethasone |
|
| 2 |
[GO] |
2026―Jun―19 |
Sars-cov-2 vaccine-inactivated-sinovac-biotech |
|
| 3 |
[GO] |
2026―Jun―19 |
Covid-19 vaccine |
|
| 4 |
[GO] |
2026―Jun―16 |
Severe acute respiratory syndrome coronavirus 2 mrna vaccine |
|
| 5 |
[GO] |
2026―Jun―16 |
Severe acute respiratory syndrome coronavirus 2 mrna vaccine |
|
| 6 |
[GO] |
2026―Jun―16 |
Covid-19 vaccine |
|
| 7 |
[GO] |
2026―Mai―23 |
Covid-19 vaccine |
|
| 8 |
[GO] |
2026―Mai―23 |
Covid-19 vaccine |
|
| 9 |
[GO] |
2026―Mai―23 |
Covid-19 vaccine |
|
| 10 |
[GO] |
2026―Mai―19 |
Covid-19 vaccine |
|
| 11 |
[GO] |
2026―Mai―19 |
Covid-19 vaccine |
|
| 12 |
[GO] |
2026―Mai―08 |
Covid-19 vaccine adjuvanted novavax |
|
| 13 |
[GO] |
2026―Apr―24 |
Covid-19 vaccine |
|
| 14 |
[GO] |
2026―Apr―20 |
Covid-19 vaccine |
|
| 15 |
[GO] |
2026―Apr―10 |
Covid-19 vaccine |
|
| 16 |
[GO] |
2026―Mrz―26 |
Severe acute respiratory syndrome coronavirus 2 mrna vaccine |
|
| 17 |
[GO] |
2026―Mrz―23 |
Covid-19 vaccine |
|
| 18 |
[GO] |
2026―Mrz―23 |
Covid-19 vaccine |
|
| 19 |
[GO] |
2026―Feb―12 |
Covid-19 vaccine |
|
| 20 |
[GO] |
2026―Feb―06 |
Covid-19 vaccine |
|
| 21 |
[GO] |
2026―Feb―03 |
Covid-19 vaccine |
|
| 22 |
[GO] |
2026―Jan―16 |
Covid-19 vaccine |
|
| 23 |
[GO] |
2026―Jan―16 |
COVID-19 vaccine |
|
| 24 |
[GO] |
2026―Jan―12 |
GP visits for VTE increase after COVID-19 vaccination |
|
| 25 |
[GO] |
2026―Jan―12 |
AstraZeneca COVID-19 vaccine-related thrombotic thrombocytopenia syndrome |
|
| 26 |
[GO] |
2026―Jan―12 |
Covid-19 vaccine |
|
| 27 |
[GO] |
2026―Jan―09 |
COVID-19 vaccines may slightly increase risk of herpes zoster |
|
| 28 |
[GO] |
2025―Dez―23 |
Covid-19 vaccines |
|
| 29 |
[GO] |
2025―Dez―20 |
Covid-19 vaccine |
|
| 30 |
[GO] |
2025―Dez―13 |
Covid-19 vaccine pfizer biontech |
|
| 31 |
[GO] |
2025―Nov―21 |
Covid-19 vaccine |
|
| 32 |
[GO] |
2025―Nov―07 |
Covid-19 vaccines |
|
| 33 |
[GO] |
2025―Nov―07 |
Covid-19 vaccines |
|
| 34 |
[GO] |
2025―Nov―07 |
Covid-19 vaccine |
|
| 35 |
[GO] |
2025―Okt―16 |
Covid-19 vaccine |
|
| 36 |
[GO] |
2025―Okt―16 |
Covid-19 vaccine |
|
| 37 |
[GO] |
2025―Okt―10 |
Covid-19 vaccine |
|
| 38 |
[GO] |
2025―Okt―10 |
Covid-19 vaccine |
|
| 39 |
[GO] |
2025―Okt―03 |
COVID-19 vaccination: AE patterns in a population in Mexico |
|
| 40 |
[GO] |
2025―Sep―20 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 41 |
[GO] |
2025―Sep―20 |
COVID-19 treatments: potential CV safety concerns identified |
|
| 42 |
[GO] |
2025―Aug―30 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/Tozinameran |
|
| 43 |
[GO] |
2025―Aug―23 |
COVID-19 vaccine-related abnormal uterine bleeding |
|
| 44 |
[GO] |
2025―Aug―16 |
COVID-19 vaccine-related risk of VTE differs between vaccine types |
|
| 45 |
[GO] |
2025―Aug―13 |
COVID-19-vaccine |
|
| 46 |
[GO] |
2025―Aug―02 |
COVID-19-vaccine/Pembrolizumab |
|
| 47 |
[GO] |
2025―Jul―26 |
COVID-19 vaccine-related oral AEs |
|
| 48 |
[GO] |
2025―Jul―18 |
AEs after mRNA, viral vector and inactivated COVID-19 vaccines |
|
| 49 |
[GO] |
2025―Jul―14 |
COVID-19-vaccine |
|
| 50 |
[GO] |
2025―Jul―02 |
Antivirals used for COVID-19 have differing AE profiles |
|
| 51 |
[GO] |
2025―Jun―21 |
COVID-19 vaccine-related AEs after administration in pregnancy |
|
| 52 |
[GO] |
2025―Jun―21 |
COVID-19 vaccine-related severe AEs in special populations |
|
| 53 |
[GO] |
2025―Jun―06 |
COVID-19-vaccine |
|
| 54 |
[GO] |
2025―Jun―06 |
Risk of GBS differs between COVID-19 vaccines |
|
| 55 |
[GO] |
2025―Mai―30 |
AEs after pneumococcal and influenza or COVID-19 vaccination |
|
| 56 |
[GO] |
2025―Mai―24 |
COVID-19-vaccine/Typhoid-vaccine |
|
| 57 |
[GO] |
2025―Mai―24 |
COVID-19-vaccine |
|
| 58 |
[GO] |
2025―Mai―24 |
COVID-19-vaccine/Remdesivir |
|
| 59 |
[GO] |
2025―Mai―09 |
COVID-19 vaccine-related neurological AEs |
|
| 60 |
[GO] |
2025―Mai―09 |
AstraZeneca COVID-19 vaccine-related AEs in UK |
|
| 61 |
[GO] |
2025―Mai―04 |
COVID-19-vaccine |
|
| 62 |
[GO] |
2025―Apr―30 |
COVID-19-vaccine |
|
| 63 |
[GO] |
2025―Apr―30 |
ICI-related severe AEs during COVID-19 pandemic |
|
| 64 |
[GO] |
2025―Apr―21 |
SARS-COV-2-vaccine-inactivated |
|
| 65 |
[GO] |
2025―Apr―21 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 66 |
[GO] |
2025―Apr―11 |
COVID-19-vaccine/Olanzapine/Risperidone |
|
| 67 |
[GO] |
2025―Apr―05 |
COVID-19 vaccine-related cerebral venous sinus thrombosis |
|
| 68 |
[GO] |
2025―Mrz―29 |
COVID-19-vaccine |
|
| 69 |
[GO] |
2025―Mrz―28 |
COVID-19-vaccine/SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 70 |
[GO] |
2025―Mrz―14 |
COVID-19-vaccine/Carboplatin/Gemcitabine |
|
| 71 |
[GO] |
2025―Mrz―14 |
Use of mABs for COVID-19 increases risk of hepatotoxicity and neutropenia |
|
| 72 |
[GO] |
2025―Feb―28 |
COVID-19-vaccine/elasomeran/tozinameran |
|
| 73 |
[GO] |
2025―Feb―25 |
COVID-19-vaccine |
|
| 74 |
[GO] |
2025―Feb―25 |
COVID-19-vaccine |
|
| 75 |
[GO] |
2025―Feb―18 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 76 |
[GO] |
2025―Feb―10 |
COVID-19-vaccine |
|
| 77 |
[GO] |
2025―Jan―31 |
COVID-19-vaccine |
|
| 78 |
[GO] |
2025―Jan―31 |
COVID-19-vaccine |
|
| 79 |
[GO] |
2025―Jan―24 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology/Tozinameran |
|
| 80 |
[GO] |
2025―Jan―16 |
COVID-19-vaccine/ipilimumab/nivolumab |
|
| 81 |
[GO] |
2025―Jan―16 |
COVID-19-vaccine |
|
| 82 |
[GO] |
2025―Jan―16 |
COVID-19-vaccine/imiquimod/prednisolone |
|
| 83 |
[GO] |
2025―Jan―16 |
COVID-19-vaccine |
|
| 84 |
[GO] |
2025―Jan―16 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 85 |
[GO] |
2025―Jan―06 |
COVID-19-vaccine |
|
| 86 |
[GO] |
2025―Jan―06 |
COVID-19-vaccine |
|
| 87 |
[GO] |
2025―Jan―06 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 88 |
[GO] |
2025―Jan―06 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 89 |
[GO] |
2024―Dez―21 |
COVID-19-vaccines |
|
| 90 |
[GO] |
2024―Dez―21 |
COVID-19-vaccine |
|
| 91 |
[GO] |
2024―Dez―07 |
COVID-19-vaccine/Hydrocortisone |
|
| 92 |
[GO] |
2024―Dez―07 |
COVID-19-vaccine |
|
| 93 |
[GO] |
2024―Dez―07 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 94 |
[GO] |
2024―Dez―07 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 95 |
[GO] |
2024―Nov―28 |
COVID-19-vaccine |
|
| 96 |
[GO] |
2024―Nov―28 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 97 |
[GO] |
2024―Nov―22 |
COVID-19-vaccine |
|
| 98 |
[GO] |
2024―Nov―22 |
COVID-19-vaccine/Sunitinib |
|
| 99 |
[GO] |
2024―Nov―22 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 100 |
[GO] |
2024―Nov―14 |
COVID-19 vaccine-related AEs in South Korea |
|
| 101 |
[GO] |
2024―Nov―14 |
COVID-19-vaccine |
|
| 102 |
[GO] |
2024―Nov―14 |
COVID-19-vaccine/Influenza-virus-vaccine/Tetanus-vaccine |
|
| 103 |
[GO] |
2024―Nov―14 |
COVID-19-vaccine/Influenza-virus-vaccine/Varicella-zoster-virus-vaccine |
|
| 104 |
[GO] |
2024―Nov―08 |
COVID-19-vaccine |
|
| 105 |
[GO] |
2024―Okt―24 |
EGFR-TKI therapy does not increase risk of COVID-19 infection |
|
| 106 |
[GO] |
2024―Okt―24 |
COVID-19-vaccine |
|
| 107 |
[GO] |
2024―Okt―18 |
COVID-19-vaccine |
|
| 108 |
[GO] |
2024―Okt―15 |
COVID-19-vaccine/Influenza-virus-vaccine/Respiratory-syncytial-virus-vaccine |
|
| 109 |
[GO] |
2024―Okt―04 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 110 |
[GO] |
2024―Sep―26 |
SARS-COV-2 vaccine inactivated Sinovac Biotech/Tozinameran |
|
| 111 |
[GO] |
2024―Sep―24 |
COVID-19-vaccine |
|
| 112 |
[GO] |
2024―Sep―24 |
COVID-19-vaccine/Ceftriaxone/Remdesivir |
|
| 113 |
[GO] |
2024―Sep―24 |
SARS-COV-2 vaccine inactivated Sinovac Biotech |
|
| 114 |
[GO] |
2024―Sep―19 |
Risk of menorrhagia after mRNA COVID-19 vaccination |
|
| 115 |
[GO] |
2024―Sep―19 |
COVID-19 vaccine-related myocarditis and myocardial injury |
|
| 116 |
[GO] |
2024―Sep―19 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 117 |
[GO] |
2024―Aug―24 |
COVID-19-vaccine |
|
| 118 |
[GO] |
2024―Aug―16 |
Paxlovid, molnupiravir and sotrovimab safe for COVID-19 infections |
|
| 119 |
[GO] |
2024―Aug―09 |
COVID-19 vaccination-related urinary tract effects |
|
| 120 |
[GO] |
2024―Aug―09 |
COVID-19 vaccine |
|
| 121 |
[GO] |
2024―Aug―09 |
COVID-19-vaccine |
|
| 122 |
[GO] |
2024―Aug―02 |
COVID-19-vaccine/Hyaluronic acid |
|
| 123 |
[GO] |
2024―Aug―02 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 124 |
[GO] |
2024―Jul―27 |
COVID-19 vaccination in first trimester: no increase in congenital abnormalities |
|
| 125 |
[GO] |
2024―Jul―27 |
COVID-19 vaccination safe during pregnancy |
|
| 126 |
[GO] |
2024―Jul―27 |
COVID-19 vaccines |
|
| 127 |
[GO] |
2024―Jul―27 |
COVID-19-vaccine |
|
| 128 |
[GO] |
2024―Jul―27 |
COVID-19-vaccine |
|
| 129 |
[GO] |
2024―Jul―27 |
COVID-19-vaccine |
|
| 130 |
[GO] |
2024―Jul―27 |
COVID-19-vaccine |
|
| 131 |
[GO] |
2024―Jul―12 |
Long-lasting lymphadenopathy after COVID-19 vaccination |
|
| 132 |
[GO] |
2024―Jul―12 |
No increase in major birth defects after exposure to mRNA COVID-19 vaccines |
|
| 133 |
[GO] |
2024―Jul―05 |
mRNA COVID-19 vaccination safe in pregnancy |
|
| 134 |
[GO] |
2024―Jul―05 |
COVID-19-vaccine |
|
| 135 |
[GO] |
2024―Jul―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 136 |
[GO] |
2024―Jul―02 |
Safety profile of COVID-19 vaccines favourable in immunocompromised people |
|
| 137 |
[GO] |
2024―Jul―02 |
COVID-19-vaccine |
|
| 138 |
[GO] |
2024―Jul―02 |
COVID-19-vaccine |
|
| 139 |
[GO] |
2024―Jul―02 |
COVID-19-vaccine/Immune-globulin/Steroids |
|
| 140 |
[GO] |
2024―Jul―02 |
COVID-19-vaccines |
|
| 141 |
[GO] |
2024―Jul―02 |
Severe acute respiratory syndrome coronavirus-2 mRNA vaccine |
|
| 142 |
[GO] |
2024―Jul―02 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 143 |
[GO] |
2024―Jun―22 |
AEs after COVID-19 vaccination are associated with nAB response |
|
| 144 |
[GO] |
2024―Jun―22 |
COVID-19-vaccine |
|
| 145 |
[GO] |
2024―Jun―22 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 146 |
[GO] |
2024―Jun―22 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
| 147 |
[GO] |
2024―Jun―19 |
COVID-19-vaccine |
|
| 148 |
[GO] |
2024―Mai―31 |
BBV-152 COVID-19 vaccine-related AESIs may persist for a year |
|
| 149 |
[GO] |
2024―Mai―31 |
COVID-19-vaccine/influenza-virus-vaccine |
|
| 150 |
[GO] |
2024―Mai―28 |
COVID-19 vaccines/immunosuppressants |
|
| 151 |
[GO] |
2024―Mai―28 |
COVID-19-vaccine |
|
| 152 |
[GO] |
2024―Mai―28 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
| 153 |
[GO] |
2024―Mai―11 |
PPI use increases risk of COVID-19 infections after two doses of COVID-19 vaccine |
|
| 154 |
[GO] |
2024―Mai―11 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
| 155 |
[GO] |
2024―Mai―03 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
| 156 |
[GO] |
2024―Mai―03 |
COVID-19-vaccine/polymethyl-methacrylate |
|
| 157 |
[GO] |
2024―Mai―03 |
COVID-19-vaccine/prednisone/tacrolimus |
|
| 158 |
[GO] |
2024―Mai―03 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 159 |
[GO] |
2024―Mai―03 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/Tozinameran |
|
| 160 |
[GO] |
2024―Apr―27 |
COVID-19 vaccine-related heavy menstrual bleeding |
|
| 161 |
[GO] |
2024―Apr―27 |
COVID-19-vaccine |
|
| 162 |
[GO] |
2024―Apr―27 |
COVID-19-vaccine |
|
| 163 |
[GO] |
2024―Apr―27 |
COVID-19-vaccine |
|
| 164 |
[GO] |
2024―Apr―27 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
| 165 |
[GO] |
2024―Apr―27 |
COVID-19-vaccine/Elasomeran |
|
| 166 |
[GO] |
2024―Apr―27 |
COVID-19-vaccine/Immune-globulin |
|
| 167 |
[GO] |
2024―Apr―27 |
COVID-19-vaccine/Olanzapine |
|
| 168 |
[GO] |
2024―Apr―27 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 169 |
[GO] |
2024―Apr―27 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 170 |
[GO] |
2024―Apr―12 |
Moderna COVID-19 vaccine may cause chronic urticaria |
|
| 171 |
[GO] |
2024―Apr―12 |
COVID-19 vaccines do not increase GP visits for menstrual disorders |
|
| 172 |
[GO] |
2024―Apr―12 |
COVID-19-vaccine |
|
| 173 |
[GO] |
2024―Apr―12 |
COVID-19-vaccine |
|
| 174 |
[GO] |
2024―Apr―12 |
COVID-19-vaccine/cilgavimab/tixagevimab |
|
| 175 |
[GO] |
2024―Apr―05 |
COVID-19-vaccine |
|
| 176 |
[GO] |
2024―Apr―05 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
| 177 |
[GO] |
2024―Apr―05 |
COVID-19-vaccine/nirmatrelvir+ritonavir/tacrolimus |
|
| 178 |
[GO] |
2024―Apr―05 |
COVID-19-vaccine/nirmatrelvir+ritonavir/tacrolimus |
|
| 179 |
[GO] |
2024―Apr―05 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 180 |
[GO] |
2024―Mrz―23 |
COVID-19 Vaccines |
|
| 181 |
[GO] |
2024―Mrz―23 |
mRNA COVID-19 vaccines not linked to postmenopausal bleeding |
|
| 182 |
[GO] |
2024―Mrz―23 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology/ibuprofen/paracetamol |
|
| 183 |
[GO] |
2024―Mrz―08 |
Co-administration of bivalent mRNA COVID-19 and influenza vaccines: no new or unexpected safety concerns |
|
| 184 |
[GO] |
2024―Mrz―08 |
COVID-19-vaccines/Immunosuppressants/Rituximab |
|
| 185 |
[GO] |
2024―Mrz―01 |
COVID-19 vaccine-related audiovestibular AEs |
|
| 186 |
[GO] |
2024―Mrz―01 |
COVID-19-vaccine |
|
| 187 |
[GO] |
2024―Mrz―01 |
COVID-19-vaccine |
|
| 188 |
[GO] |
2024―Mrz―01 |
COVID-19-vaccines/Prednisone/Valaciclovir |
|
| 189 |
[GO] |
2024―Feb―22 |
COVID-19 vaccine |
|
| 190 |
[GO] |
2024―Feb―22 |
Risks of neonatal AEs after mRNA COVID-19 vaccine exposure |
|
| 191 |
[GO] |
2024―Feb―22 |
Global COVID-19 vaccine study confirms safety signals |
|
| 192 |
[GO] |
2024―Feb―09 |
COVID-19-vaccine |
|
| 193 |
[GO] |
2024―Feb―09 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/thiamazole |
|
| 194 |
[GO] |
2024―Feb―02 |
Insufficient evidence to link Long COVID to COVID-19 vaccines |
|
| 195 |
[GO] |
2024―Feb―02 |
In utero exposure to COVID-19 vaccines has no neurodevelopmental impact |
|
| 196 |
[GO] |
2024―Jan―25 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology/hydrocortisone |
|
| 197 |
[GO] |
2024―Jan―13 |
Differences in rates of AESIs between COVID-19 vaccine types |
|
| 198 |
[GO] |
2024―Jan―13 |
COVID-19-vaccine |
|
| 199 |
[GO] |
2024―Jan―13 |
COVID-19-vaccine/lamotrigine |
|
| 200 |
[GO] |
2024―Jan―13 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 201 |
[GO] |
2024―Jan―13 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 202 |
[GO] |
2024―Jan―05 |
Sudden deafness reported after COVID-19 vaccination |
|
| 203 |
[GO] |
2024―Jan―05 |
COVID-19 Vaccines |
|
| 204 |
[GO] |
2024―Jan―05 |
COVID-19-vaccine |
|
| 205 |
[GO] |
2024―Jan―05 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
| 206 |
[GO] |
2023―Dez―22 |
No risk of respiratory exacerbation after COVID-19 vaccination |
|
| 207 |
[GO] |
2023―Dez―14 |
Corticosteroids/cyclophosphamide/severe acute respiratory syndrome coronavirus 2 mRNA vaccine |
|
| 208 |
[GO] |
2023―Dez―12 |
COVID-19 vaccine |
|
| 209 |
[GO] |
2023―Dez―12 |
Covid-19-vaccine |
|
| 210 |
[GO] |
2023―Dez―12 |
COVID-19-vaccine/tamoxifen |
|
| 211 |
[GO] |
2023―Dez―12 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 212 |
[GO] |
2023―Dez―12 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech/tozinameran |
|
| 213 |
[GO] |
2023―Dez―12 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech/tozinameran |
|
| 214 |
[GO] |
2023―Dez―04 |
COVID-19-vaccine |
|
| 215 |
[GO] |
2023―Dez―04 |
Covid-19-vaccine/hyaluronic-acid/tozinameran |
|
| 216 |
[GO] |
2023―Dez―01 |
COVID-19-vaccine |
|
| 217 |
[GO] |
2023―Dez―01 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech/tozinameran |
|
| 218 |
[GO] |
2023―Nov―25 |
COVID-19 vaccination: large impact on reporting of ADRs not related to COVID-19 vaccines in France |
|
| 219 |
[GO] |
2023―Nov―25 |
mRNA COVID-19 vaccine: side effects more common, recovery prolonged among females and younger adults |
|
| 220 |
[GO] |
2023―Nov―25 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/immune-globulin |
|
| 221 |
[GO] |
2023―Nov―25 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 222 |
[GO] |
2023―Nov―09 |
COVID-19 vaccine |
|
| 223 |
[GO] |
2023―Nov―09 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 224 |
[GO] |
2023―Nov―03 |
Pfizer-BioNTech COVID-19 vaccination safe in adolescents with CKD |
|
| 225 |
[GO] |
2023―Nov―03 |
SARS-COV-2 vaccine inactivated Sinovac Biotech |
|
| 226 |
[GO] |
2023―Nov―03 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 227 |
[GO] |
2023―Okt―27 |
ICMRA statement on safety of COVID-19 vaccines |
|
| 228 |
[GO] |
2023―Okt―27 |
COVID-19-vaccine |
|
| 229 |
[GO] |
2023―Okt―27 |
Covid-19-vaccine/methotrexate |
|
| 230 |
[GO] |
2023―Okt―27 |
COVID-19-vaccines |
|
| 231 |
[GO] |
2023―Okt―19 |
COVID-19-vaccine |
|
| 232 |
[GO] |
2023―Okt―19 |
Covid-19-vaccine |
|
| 233 |
[GO] |
2023―Sep―29 |
Severe acute respiratory syndrome coronavirus-2 mRNA vaccine |
|
| 234 |
[GO] |
2023―Sep―21 |
AstraZeneca COVID-19 vaccine-related pityriasis rosea |
|
| 235 |
[GO] |
2023―Sep―21 |
AstraZeneca COVID-19 vaccine-related retinal vein occlusion |
|
| 236 |
[GO] |
2023―Sep―21 |
SARS-COV-2-vaccine-inactivated |
|
| 237 |
[GO] |
2023―Sep―18 |
COVID-19 vaccination does not increase risk of preterm labour |
|
| 238 |
[GO] |
2023―Sep―18 |
Safety signal of CIDP with use of AstraZeneca COVID-19 vaccine |
|
| 239 |
[GO] |
2023―Sep―18 |
COVID-19-vaccine |
|
| 240 |
[GO] |
2023―Sep―18 |
Covid-19-vaccine |
|
| 241 |
[GO] |
2023―Sep―18 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
| 242 |
[GO] |
2023―Sep―18 |
Covid-19-vaccine-pfizer-biontech |
|
| 243 |
[GO] |
2023―Sep―18 |
COVID-19-vaccines |
|
| 244 |
[GO] |
2023―Sep―08 |
Antibacterial use prior to COVID-19 vaccination increases risk of COVID-19 infection |
|
| 245 |
[GO] |
2023―Sep―08 |
Shoulder injury after Pfizer-BioNTech COVID-19 vaccine |
|
| 246 |
[GO] |
2023―Sep―08 |
COVID-19 vaccine/nirmatrelvir+ritonavir |
|
| 247 |
[GO] |
2023―Sep―01 |
COVID-19 vaccines/immunosuppressants/Varicella zoster virus vaccine |
|
| 248 |
[GO] |
2023―Sep―01 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 249 |
[GO] |
2023―Aug―25 |
Low risk of urticaria exacerbation following COVID-19 vaccination |
|
| 250 |
[GO] |
2023―Aug―25 |
COVID-19 vaccine |
|
| 251 |
[GO] |
2023―Aug―25 |
Pfizer-BioNTech COVID-19 vaccine increases risk of myocarditis/pericarditis |
|
| 252 |
[GO] |
2023―Aug―25 |
AEs and rheumatic disease flares after COVID-19 vaccine versus influenza vaccine |
|
| 253 |
[GO] |
2023―Aug―25 |
Novavax COVID-19 vaccine: no new safety concerns |
|
| 254 |
[GO] |
2023―Aug―25 |
COVID-19-vaccine |
|
| 255 |
[GO] |
2023―Aug―25 |
COVID-19-vaccine |
|
| 256 |
[GO] |
2023―Aug―25 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
| 257 |
[GO] |
2023―Aug―25 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 258 |
[GO] |
2023―Aug―18 |
Bivalent mRNA COVID-19 booster vaccines safe in adults |
|
| 259 |
[GO] |
2023―Aug―18 |
Co-administered influenza vaccine and mRNA COVID-19 vaccine safe |
|
| 260 |
[GO] |
2023―Aug―18 |
COVID-19-vaccine |
|
| 261 |
[GO] |
2023―Aug―18 |
COVID-19-vaccines/methylprednisolone |
|
| 262 |
[GO] |
2023―Aug―18 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 263 |
[GO] |
2023―Aug―11 |
Nirmatrelvir/ritonavir well tolerated for COVID-19 in patients with CKD |
|
| 264 |
[GO] |
2023―Aug―11 |
No association between mRNA COVID-19 vaccines and menorrhagia |
|
| 265 |
[GO] |
2023―Aug―04 |
Covid-19-vaccine |
|
| 266 |
[GO] |
2023―Jul―28 |
Covid-19-vaccine |
|
| 267 |
[GO] |
2023―Jul―28 |
COVID-19-vaccine |
|
| 268 |
[GO] |
2023―Jul―28 |
COVID-19-vaccines/disease-modifying-antirheumatics interaction |
|
| 269 |
[GO] |
2023―Jul―28 |
Severe acute respiratory syndrome coronavirus 2 mrna vaccine |
|
| 270 |
[GO] |
2023―Jul―21 |
Societal burden of opioid toxicity-related deaths in the US worsened during COVID-19 pandemic |
|
| 271 |
[GO] |
2023―Jul―21 |
Immediate ADRs after COVID-19 vaccination in Denmark |
|
| 272 |
[GO] |
2023―Jul―21 |
Novavax COVID-19 vaccine NVX-CoV2373 safe in older adults |
|
| 273 |
[GO] |
2023―Jul―21 |
COVID-19 vaccine-related autoimmune haemolytic anaemia |
|
| 274 |
[GO] |
2023―Jul―21 |
COVID-19 vaccine-related menstruation disorders |
|
| 275 |
[GO] |
2023―Jul―21 |
Covid-19-vaccine/immune-globulin |
|
| 276 |
[GO] |
2023―Jul―21 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 277 |
[GO] |
2023―Jul―14 |
No major differences in AEs between COVID-19 vaccination schedules |
|
| 278 |
[GO] |
2023―Jul―14 |
EMA endorses statement on safety of COVID-19 vaccines issued by ICMRA |
|
| 279 |
[GO] |
2023―Jul―14 |
COVID-19-vaccine/dexamethasone/tocilizumab |
|
| 280 |
[GO] |
2023―Jul―14 |
SARS-COV-2-vaccine-inactivated-sinovac-biotech/tozinameran |
|
| 281 |
[GO] |
2023―Jul―14 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech/zf-2001 |
|
| 282 |
[GO] |
2023―Jul―07 |
COVID-19 vaccine-related hypersensitivity: basophil reactivity |
|
| 283 |
[GO] |
2023―Jul―07 |
EMA publishes report on ensuring safety of COVID-19 vaccines |
|
| 284 |
[GO] |
2023―Jul―07 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 285 |
[GO] |
2023―Jul―07 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 286 |
[GO] |
2023―Jun―30 |
COVID-19-vaccine |
|
| 287 |
[GO] |
2023―Jun―30 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
| 288 |
[GO] |
2023―Jun―30 |
Covid-19-vaccine |
|
| 289 |
[GO] |
2023―Jun―30 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 290 |
[GO] |
2023―Jun―23 |
Covid-19-vaccine/fondaparinux-sodium |
|
| 291 |
[GO] |
2023―Jun―23 |
COVID-19 vaccination and cyclophosphamide |
|
| 292 |
[GO] |
2023―Jun―23 |
Transverse myelitis after COVID-19 vaccination |
|
| 293 |
[GO] |
2023―Jun―23 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 294 |
[GO] |
2023―Jun―23 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 295 |
[GO] |
2023―Jun―16 |
Covid-19-vaccine |
|
| 296 |
[GO] |
2023―Jun―16 |
Covid-19-vaccine |
|
| 297 |
[GO] |
2023―Jun―16 |
COVID-19 vaccines |
|
| 298 |
[GO] |
2023―Jun―16 |
Third mRNA COVID-19 vaccine dose well tolerated in infants and young children |
|
| 299 |
[GO] |
2023―Jun―16 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 300 |
[GO] |
2023―Jun―09 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
| 301 |
[GO] |
2023―Jun―09 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/dabigatran-etexilate/dipyrone |
|
| 302 |
[GO] |
2023―Jun―09 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 303 |
[GO] |
2023―Jun―02 |
Covid-19-vaccine |
|
| 304 |
[GO] |
2023―Jun―02 |
Covid-19-vaccine |
|
| 305 |
[GO] |
2023―Jun―02 |
Covid-19-vaccine |
|
| 306 |
[GO] |
2023―Jun―02 |
BNT162b2 COVID-19 vaccine safe in children, signal for myocarditis/pericarditis in adolescents |
|
| 307 |
[GO] |
2023―Mai―26 |
COVID-19-vaccine |
|
| 308 |
[GO] |
2023―Mai―18 |
Covid-19-vaccine/nirmatrelvir+ritonavir/tacrolimus |
|
| 309 |
[GO] |
2023―Mai―18 |
Covid-19-vaccine |
|
| 310 |
[GO] |
2023―Mai―18 |
Nirmatrelvir+ritonavir-related AEs in patients with COVID-19 infections |
|
| 311 |
[GO] |
2023―Mai―18 |
Associations between COVID-19 vaccination and menstruation disorders "weak and inconsistent" |
|
| 312 |
[GO] |
2023―Mai―18 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 313 |
[GO] |
2023―Mai―18 |
SARS-COV-2-vaccine-inactivated-sinovac-biotech |
|
| 314 |
[GO] |
2023―Mai―12 |
Covid-19-vaccine |
|
| 315 |
[GO] |
2023―Mai―12 |
Covid-19-vaccine |
|
| 316 |
[GO] |
2023―Mai―12 |
COVID-19-vaccine/dexamethasone |
|
| 317 |
[GO] |
2023―Mai―12 |
Covid-19-vaccine |
|
| 318 |
[GO] |
2023―Mai―12 |
Long-term safety of AstraZeneca COVID-19 vaccine |
|
| 319 |
[GO] |
2023―Mai―05 |
COVID-19-vaccines |
|
| 320 |
[GO] |
2023―Mai―05 |
COVID-19 vaccine-related ADRs in children and adolescents |
|
| 321 |
[GO] |
2023―Mai―05 |
COVID-19 vaccine in adolescents: no new serious safety concerns identified |
|
| 322 |
[GO] |
2023―Mai―05 |
Viral vector-based COVID-19 vaccines: risk of thrombosis with thrombocytopenia |
|
| 323 |
[GO] |
2023―Mai―05 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 324 |
[GO] |
2023―Apr―28 |
COVID-19-vaccines |
|
| 325 |
[GO] |
2023―Apr―28 |
COVID-19-vaccine/nivolumab |
|
| 326 |
[GO] |
2023―Apr―28 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 327 |
[GO] |
2023―Apr―28 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 328 |
[GO] |
2023―Apr―28 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 329 |
[GO] |
2023―Apr―21 |
COVID-19-vaccines |
|
| 330 |
[GO] |
2023―Apr―21 |
Covid-19-vaccine |
|
| 331 |
[GO] |
2023―Apr―21 |
Covid-19 vaccines |
|
| 332 |
[GO] |
2023―Apr―21 |
Vulval aphthous ulcers in adolescents after COVID-19 vaccination |
|
| 333 |
[GO] |
2023―Apr―21 |
mRNA COVID-19 vaccination not associated with retinal vascular occlusion |
|
| 334 |
[GO] |
2023―Apr―14 |
COVID-19-vaccines/glucocorticoids |
|
| 335 |
[GO] |
2023―Apr―14 |
Covid-19-vaccine/nirmatrelvir/ritonavir |
|
| 336 |
[GO] |
2023―Apr―14 |
COVID-19-vaccine/elasomeran |
|
| 337 |
[GO] |
2023―Apr―14 |
Covid-19 vaccine |
|
| 338 |
[GO] |
2023―Apr―14 |
COVID-19 vaccination: serious AEs and AESIs rare |
|
| 339 |
[GO] |
2023―Apr―06 |
Covid-19-vaccine |
|
| 340 |
[GO] |
2023―Apr―06 |
COVID-19 vaccination safety during pregnancy |
|
| 341 |
[GO] |
2023―Apr―06 |
Experiences after first COVID-19 vaccination impact severity of AEs after second dose |
|
| 342 |
[GO] |
2023―Apr―06 |
SARS-Cov-2-vaccine-inactivated-Sinovac-Biotech |
|
| 343 |
[GO] |
2023―Apr―06 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
| 344 |
[GO] |
2023―Mrz―31 |
Covid-19-vaccine |
|
| 345 |
[GO] |
2023―Mrz―31 |
Covid-19-vaccine |
|
| 346 |
[GO] |
2023―Mrz―31 |
COVID-19-vaccine |
|
| 347 |
[GO] |
2023―Mrz―31 |
SARS-COV-2-vaccine-inactivated |
|
| 348 |
[GO] |
2023―Mrz―31 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 349 |
[GO] |
2023―Mrz―25 |
Covid-19-vaccine/elasomeran/tozinameran |
|
| 350 |
[GO] |
2023―Mrz―25 |
Covid-19-vaccine/obinutuzumab |
|
| 351 |
[GO] |
2023―Mrz―25 |
Covid-19-vaccine-pfizer-biontech |
|
| 352 |
[GO] |
2023―Mrz―25 |
COVID-19-vaccine |
|
| 353 |
[GO] |
2023―Mrz―25 |
Covid-19 vaccine |
|
| 354 |
[GO] |
2023―Mrz―23 |
Covid-19-vaccine |
|
| 355 |
[GO] |
2023―Mrz―23 |
Covid-19-vaccine |
|
| 356 |
[GO] |
2023―Mrz―23 |
COVID-19-vaccine |
|
| 357 |
[GO] |
2023―Mrz―23 |
Covid-19-vaccine |
|
| 358 |
[GO] |
2023―Mrz―23 |
COVID-19 vaccine-related Guillain-Barre syndrome |
|
| 359 |
[GO] |
2023―Mrz―10 |
COVID-19 vaccine |
|
| 360 |
[GO] |
2023―Mrz―10 |
Anxiety and depression increase risk of reporting COVID-19 vaccine-related AEs |
|
| 361 |
[GO] |
2023―Mrz―10 |
Covid-19-vaccine |
|
| 362 |
[GO] |
2023―Mrz―10 |
Sars-cov-2 vaccine-inactivated-sinovac-biotech |
|
| 363 |
[GO] |
2023―Mrz―10 |
SARS-COV-2-vaccine-inactivated-sinovac-biotech |
|
| 364 |
[GO] |
2023―Mrz―03 |
African countries report fewer AEFIs after COVID-19 vaccination than RoW |
|
| 365 |
[GO] |
2023―Mrz―03 |
COVID-19 vaccine |
|
| 366 |
[GO] |
2023―Mrz―03 |
Novavax COVID-19 vaccine-related myocarditis/pericarditis |
|
| 367 |
[GO] |
2023―Mrz―03 |
HPRA safety update on COVID-19 vaccines up to January 2023 |
|
| 368 |
[GO] |
2023―Mrz―03 |
COVID-19-vaccine |
|
| 369 |
[GO] |
2023―Mrz―03 |
COVID-19-vaccine/rosuvastatin |
|
| 370 |
[GO] |
2023―Mrz―03 |
COVID-19-vaccines/fondaparinux-sodium/mannitol |
|
| 371 |
[GO] |
2023―Mrz―03 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 372 |
[GO] |
2023―Feb―25 |
More AEFIs reported after COVID-19 vaccination in females than in males |
|
| 373 |
[GO] |
2023―Feb―25 |
COVID-19 vaccine |
|
| 374 |
[GO] |
2023―Feb―25 |
Covid-19 vaccine/rituximab |
|
| 375 |
[GO] |
2023―Feb―25 |
COVID-19-vaccine |
|
| 376 |
[GO] |
2023―Feb―25 |
COVID-19-vaccine |
|
| 377 |
[GO] |
2023―Feb―25 |
COVID-19-vaccine |
|
| 378 |
[GO] |
2023―Feb―25 |
Covid-19-vaccine |
|
| 379 |
[GO] |
2023―Feb―25 |
COVID-19-vaccine |
|
| 380 |
[GO] |
2023―Feb―25 |
Covid-19-vaccine |
|
| 381 |
[GO] |
2023―Feb―25 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
| 382 |
[GO] |
2023―Feb―25 |
Covid-19-vaccines |
|
| 383 |
[GO] |
2023―Feb―25 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 384 |
[GO] |
2023―Feb―25 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 385 |
[GO] |
2023―Feb―17 |
Adverse events following COVID-19 vaccination common but mild in haemodialysis patients |
|
| 386 |
[GO] |
2023―Feb―17 |
Covid-19-vaccine |
|
| 387 |
[GO] |
2023―Feb―17 |
COVID-19-vaccines |
|
| 388 |
[GO] |
2023―Feb―11 |
COVID-19 rebound after use of Paxlovid |
|
| 389 |
[GO] |
2023―Feb―11 |
Pregnant women have known AEs after COVID-19 vaccination |
|
| 390 |
[GO] |
2023―Feb―11 |
COVID-19 vaccine |
|
| 391 |
[GO] |
2023―Feb―11 |
COVID-19 vaccine |
|
| 392 |
[GO] |
2023―Feb―11 |
COVID-19 vaccine |
|
| 393 |
[GO] |
2023―Feb―11 |
COVID-19 vaccine/rituximab |
|
| 394 |
[GO] |
2023―Feb―11 |
Covid-19-vaccine |
|
| 395 |
[GO] |
2023―Feb―11 |
COVID-19-vaccine/influenza-virus-vaccine |
|
| 396 |
[GO] |
2023―Feb―11 |
Covid-19-vaccine/methylprednisolone |
|
| 397 |
[GO] |
2023―Feb―11 |
COVID-19-vaccines/prednisone |
|
| 398 |
[GO] |
2023―Feb―11 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 399 |
[GO] |
2023―Feb―11 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 400 |
[GO] |
2023―Feb―11 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 401 |
[GO] |
2023―Feb―11 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
| 402 |
[GO] |
2023―Feb―03 |
COVID-19-vaccine |
|
| 403 |
[GO] |
2023―Feb―03 |
SARS-COV-2-vaccine-inactivated-sinovac-biotech |
|
| 404 |
[GO] |
2023―Jan―30 |
Safety of co-administered mRNA COVID-19 and influenza vaccines |
|
| 405 |
[GO] |
2023―Jan―30 |
Cilgavimab/tixagevimab unlikely to be active against some COVID-19 Omicron subvariants |
|
| 406 |
[GO] |
2023―Jan―30 |
COVID-19 vaccine |
|
| 407 |
[GO] |
2023―Jan―30 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
| 408 |
[GO] |
2023―Jan―30 |
COVID-19-vaccine/nirmatrelvir+ritonavir |
|
| 409 |
[GO] |
2023―Jan―20 |
Thyroid dysfunction after COVID-19 vaccination |
|
| 410 |
[GO] |
2023―Jan―20 |
COVID-19-vaccine |
|
| 411 |
[GO] |
2023―Jan―20 |
COVID-19-vaccine |
|
| 412 |
[GO] |
2023―Jan―20 |
COVID-19-vaccines/dexamethasone/tocilizumab |
|
| 413 |
[GO] |
2023―Jan―20 |
Sars-cov-2-vaccine inactivated sinovac biotech |
|
| 414 |
[GO] |
2023―Jan―20 |
Sars-cov-2-vaccine inactivated sinovac biotech |
|
| 415 |
[GO] |
2023―Jan―15 |
Coronavirus-vaccine-stemirna-therapeutics/tongji-university |
|
| 416 |
[GO] |
2023―Jan―15 |
Covid-19-vaccine |
|
| 417 |
[GO] |
2023―Jan―15 |
Covid-19-vaccine/tozinameran |
|
| 418 |
[GO] |
2023―Jan―15 |
No new safety signals after COVID-19 vaccination in New Zealand |
|
| 419 |
[GO] |
2023―Jan―14 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 420 |
[GO] |
2023―Jan―14 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 421 |
[GO] |
2023―Jan―14 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 422 |
[GO] |
2023―Jan―14 |
COVID-19-vaccines |
|
| 423 |
[GO] |
2023―Jan―14 |
Covid-19-vaccine-pfizer-biontech/remdesivir |
|
| 424 |
[GO] |
2023―Jan―14 |
Covid-19-vaccine/peginterferon-alfa-2a |
|
| 425 |
[GO] |
2023―Jan―14 |
COVID-19-vaccine |
|
| 426 |
[GO] |
2023―Jan―14 |
COVID-19-vaccine |
|
| 427 |
[GO] |
2023―Jan―14 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
| 428 |
[GO] |
2023―Jan―14 |
COVID-19-vaccine |
|
| 429 |
[GO] |
2023―Jan―14 |
Covid-19-vaccine |
|
| 430 |
[GO] |
2023―Jan―14 |
Covid-19-vaccine |
|
| 431 |
[GO] |
2023―Jan―14 |
Covid-19-vaccine |
|
| 432 |
[GO] |
2023―Jan―14 |
Covid-19-vaccine |
|
| 433 |
[GO] |
2023―Jan―14 |
COVID-19 vaccines |
|
| 434 |
[GO] |
2023―Jan―14 |
POTS less frequent after COVID-19 vaccine than after COVID infection |
|
| 435 |
[GO] |
2023―Jan―14 |
COVID-19 vaccine |
|
| 436 |
[GO] |
2022―Dez―16 |
ADRs following use of oral COVID-19 therapeutics (Paxlovid, Lagevrio) in New Zealand |
|
| 437 |
[GO] |
2022―Dez―16 |
Covid-19-vaccine |
|
| 438 |
[GO] |
2022―Dez―16 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
| 439 |
[GO] |
2022―Dez―16 |
Sars-cov-2-vaccine-inactivated |
|
| 440 |
[GO] |
2022―Dez―10 |
FDA drug safety surveillance during COVID-19 pandemic |
|
| 441 |
[GO] |
2022―Dez―10 |
COVID-19 vaccine |
|
| 442 |
[GO] |
2022―Dez―10 |
Safety of second Pfizer-BioNTech COVID-19 vaccine booster |
|
| 443 |
[GO] |
2022―Dez―10 |
Covid-19-vaccine |
|
| 444 |
[GO] |
2022―Dez―10 |
Covid-19-vaccine |
|
| 445 |
[GO] |
2022―Dez―10 |
Covid-19-vaccine |
|
| 446 |
[GO] |
2022―Dez―10 |
Covid-19-vaccine |
|
| 447 |
[GO] |
2022―Dez―10 |
COVID-19-vaccine/nivolumab/pembrolizumab |
|
| 448 |
[GO] |
2022―Dez―10 |
Covid-19-vaccine/ocrelizumab |
|
| 449 |
[GO] |
2022―Dez―10 |
SARS-COV-2-vaccine-inactivated-sinovac-biotech |
|
| 450 |
[GO] |
2022―Dez―10 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
| 451 |
[GO] |
2022―Dez―02 |
COVID-19 vaccines safe in patients with systemic lupus erythematosus |
|
| 452 |
[GO] |
2022―Dez―02 |
COVID-19-vaccine |
|
| 453 |
[GO] |
2022―Dez―02 |
Covid-19-vaccine |
|
| 454 |
[GO] |
2022―Dez―02 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
| 455 |
[GO] |
2022―Dez―02 |
Covid-19-vaccine/elasomeran/tozinameran |
|
| 456 |
[GO] |
2022―Dez―02 |
COVID-19-vaccines/immunosuppressants/tocilizumab |
|
| 457 |
[GO] |
2022―Nov―28 |
Severe AEs after COVID-19 vaccination following COVID-19 infection |
|
| 458 |
[GO] |
2022―Nov―28 |
Dedicated system for COVID-19 vaccine safety surveillance at Lareb |
|
| 459 |
[GO] |
2022―Nov―28 |
COVID-19 vaccine-associated Guillain-Barre syndrome |
|
| 460 |
[GO] |
2022―Nov―28 |
COVID-19-vaccine |
|
| 461 |
[GO] |
2022―Nov―28 |
Covid-19-vaccine |
|
| 462 |
[GO] |
2022―Nov―28 |
COVID-19-vaccines |
|
| 463 |
[GO] |
2022―Nov―28 |
COVID-19-vaccines/prednisone |
|
| 464 |
[GO] |
2022―Nov―28 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
| 465 |
[GO] |
2022―Nov―19 |
COVID-19 vaccine-related neuralgic amyotrophy |
|
| 466 |
[GO] |
2022―Nov―19 |
Pfizer-BioNTech and Moderna COVID-19 vaccines safe in Japan |
|
| 467 |
[GO] |
2022―Nov―19 |
COVID-19-vaccine |
|
| 468 |
[GO] |
2022―Nov―19 |
Covid-19-vaccine |
|
| 469 |
[GO] |
2022―Nov―19 |
COVID-19-vaccine/propylthiouracil |
|
| 470 |
[GO] |
2022―Nov―11 |
Pfizer-BioNTech COVID-19 vaccination in children: no serious AEs |
|
| 471 |
[GO] |
2022―Nov―11 |
Covid-19-vaccine |
|
| 472 |
[GO] |
2022―Nov―11 |
Covid-19-vaccine |
|
| 473 |
[GO] |
2022―Nov―11 |
COVID-19-vaccine |
|
| 474 |
[GO] |
2022―Nov―11 |
Covid-19-vaccine |
|
| 475 |
[GO] |
2022―Nov―11 |
Covid-19-vaccine |
|
| 476 |
[GO] |
2022―Nov―11 |
COVID-19-vaccines |
|
| 477 |
[GO] |
2022―Nov―07 |
Risks of thrombosis and thromboembolic events after first COVID-19 vaccination |
|
| 478 |
[GO] |
2022―Nov―07 |
No pregnancy complications after use of mRNA COVID-19 vaccines |
|
| 479 |
[GO] |
2022―Nov―07 |
Covid-19-vaccine |
|
| 480 |
[GO] |
2022―Nov―07 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
| 481 |
[GO] |
2022―Nov―07 |
COVID-19-vaccines/immune-globulin/methylprednisolone |
|
| 482 |
[GO] |
2022―Okt―28 |
AEs in children after Pfizer-BioNTech COVID-19 vaccine |
|
| 483 |
[GO] |
2022―Okt―28 |
Safety of BNT162b2 COVID-19 vaccine comparable to that of other approved vaccines in young children |
|
| 484 |
[GO] |
2022―Okt―28 |
Risk of COVID-19 vaccine-related tinnitus |
|
| 485 |
[GO] |
2022―Okt―28 |
Covid-19-vaccine |
|
| 486 |
[GO] |
2022―Okt―28 |
Covid-19-vaccine |
|
| 487 |
[GO] |
2022―Okt―28 |
COVID-19-vaccine/immune-globulin/methylprednisolone |
|
| 488 |
[GO] |
2022―Okt―28 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 489 |
[GO] |
2022―Okt―28 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 490 |
[GO] |
2022―Okt―21 |
Multiple sclerosis immunotherapies increase risk of COVID-19 mortality |
|
| 491 |
[GO] |
2022―Okt―21 |
AEs after COVID-19 vaccination in patients with epilepsy |
|
| 492 |
[GO] |
2022―Okt―21 |
COVID-19 vaccine-related anaphylaxis and other allergic reactions |
|
| 493 |
[GO] |
2022―Okt―21 |
COVID-19-vaccine |
|
| 494 |
[GO] |
2022―Okt―21 |
Covid-19-vaccine |
|
| 495 |
[GO] |
2022―Okt―21 |
Covid-19-vaccine |
|
| 496 |
[GO] |
2022―Okt―21 |
Covid-19-vaccine |
|
| 497 |
[GO] |
2022―Okt―21 |
Covid-19-vaccine |
|
| 498 |
[GO] |
2022―Okt―21 |
Covid-19-vaccine |
|
| 499 |
[GO] |
2022―Okt―21 |
COVID-19-vaccine-pfizer-biontech/lisinopril/metoprolol |
|
| 500 |
[GO] |
2022―Okt―21 |
COVID-19-vaccine/temozolomide |
|
| 501 |
[GO] |
2022―Okt―21 |
COVID-19-vaccines |
|
| 502 |
[GO] |
2022―Okt―21 |
COVID-19-vaccines |
|
| 503 |
[GO] |
2022―Okt―14 |
mRNA COVID-19 vaccine safety in recipients aged 12 to 64 years |
|
| 504 |
[GO] |
2022―Okt―14 |
Covid-19-vaccine |
|
| 505 |
[GO] |
2022―Okt―14 |
COVID-19-vaccine |
|
| 506 |
[GO] |
2022―Okt―14 |
Covid-19-vaccine/elasomeran/tozinameran |
|
| 507 |
[GO] |
2022―Okt―14 |
Covid-19-vaccine/olanzapine |
|
| 508 |
[GO] |
2022―Okt―14 |
SARS-COV-2 vaccine inactivated Sinovac Biotech |
|
| 509 |
[GO] |
2022―Okt―14 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 510 |
[GO] |
2022―Okt―14 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 511 |
[GO] |
2022―Okt―07 |
COVID-19 vaccination may trigger tattoo skin reactions |
|
| 512 |
[GO] |
2022―Okt―07 |
Coronavirus-vaccine |
|
| 513 |
[GO] |
2022―Okt―07 |
Coronavirus-vaccine-stemirna-therapeutics/tongji-university/tozinameran |
|
| 514 |
[GO] |
2022―Okt―07 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
| 515 |
[GO] |
2022―Okt―01 |
Headache common after COVID-19 vaccination |
|
| 516 |
[GO] |
2022―Okt―01 |
COVID-19 vaccine |
|
| 517 |
[GO] |
2022―Okt―01 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 518 |
[GO] |
2022―Sep―23 |
Myocardial injury after 4th dose of Pfizer-BioNTech COVID-19 vaccine |
|
| 519 |
[GO] |
2022―Sep―23 |
Novavax COVID-19 vaccine-related myocarditis and pericarditis |
|
| 520 |
[GO] |
2022―Sep―23 |
Side effects common after first dose of COVID-19 vaccine: a survey from Spain |
|
| 521 |
[GO] |
2022―Sep―23 |
COVID-19-vaccine |
|
| 522 |
[GO] |
2022―Sep―23 |
COVID-19-vaccine |
|
| 523 |
[GO] |
2022―Sep―23 |
Covid-19-vaccine |
|
| 524 |
[GO] |
2022―Sep―23 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
| 525 |
[GO] |
2022―Sep―23 |
Covid-19-vaccine/methotrexate/tumour-necrosis-factor-inhibitors |
|
| 526 |
[GO] |
2022―Sep―23 |
COVID-19-vaccines/prednisolone/rituximab |
|
| 527 |
[GO] |
2022―Sep―16 |
COVID-19 outcome not worsened by remdesivir-induced bradycardia |
|
| 528 |
[GO] |
2022―Sep―16 |
Serious AEs of special interest after mRNA COVID-19 vaccination |
|
| 529 |
[GO] |
2022―Sep―16 |
COVID-19 vaccine |
|
| 530 |
[GO] |
2022―Sep―16 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 531 |
[GO] |
2022―Sep―16 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 532 |
[GO] |
2022―Sep―09 |
TTS rare after AstraZeneca COVID-19 vaccine |
|
| 533 |
[GO] |
2022―Sep―09 |
Safety profile of BBV152 COVID-19 vaccine favourable in adolescents in India |
|
| 534 |
[GO] |
2022―Sep―09 |
Covid-19-vaccine |
|
| 535 |
[GO] |
2022―Sep―09 |
Covid-19-vaccine/elasomeran |
|
| 536 |
[GO] |
2022―Sep―02 |
COVID-19 vaccination safe during pregnancy |
|
| 537 |
[GO] |
2022―Sep―02 |
COVID-19 vaccine |
|
| 538 |
[GO] |
2022―Sep―02 |
AstraZeneca, Pfizer-BioNTech, Sinopharm, Sputnik V COVID-19 vaccine |
|
| 539 |
[GO] |
2022―Sep―02 |
Covid-19 vaccine Gamaleya national research center of epidemiology and microbiology/fenoterol/ipratropium bromide |
|
| 540 |
[GO] |
2022―Sep―02 |
Adenoviral-based COVID-19 vaccines may increase risk of MI and PE |
|
| 541 |
[GO] |
2022―Sep―02 |
COVID-19-vaccine |
|
| 542 |
[GO] |
2022―Sep―02 |
COVID-19-vaccine |
|
| 543 |
[GO] |
2022―Sep―02 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 544 |
[GO] |
2022―Sep―02 |
SARS-COV-2 vaccine-inactivated Sinovac-Biotech |
|
| 545 |
[GO] |
2022―Sep―02 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 546 |
[GO] |
2022―Aug―26 |
COVID-19 mRNA vaccines safe in pregnancy |
|
| 547 |
[GO] |
2022―Aug―26 |
COVID-19 vaccination hesitancy may drive AE reporting |
|
| 548 |
[GO] |
2022―Aug―26 |
Novavax COVID-19 vaccine-related myocarditis, pericarditis |
|
| 549 |
[GO] |
2022―Aug―26 |
Covid-19-vaccine |
|
| 550 |
[GO] |
2022―Aug―26 |
COVID-19-vaccine/dexamethasone/tobramycin |
|
| 551 |
[GO] |
2022―Aug―19 |
Cutaneous reactions after COVID-19 vaccination |
|
| 552 |
[GO] |
2022―Aug―19 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
| 553 |
[GO] |
2022―Aug―19 |
COVID-19-vaccines/immune globulin |
|
| 554 |
[GO] |
2022―Aug―12 |
Serious AEs uncommon after second mRNA COVID-19 booster |
|
| 555 |
[GO] |
2022―Aug―12 |
AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia case fatalities |
|
| 556 |
[GO] |
2022―Aug―12 |
COVID-19 vaccines: risk of oral adverse events |
|
| 557 |
[GO] |
2022―Aug―12 |
Covid-19-vaccine |
|
| 558 |
[GO] |
2022―Aug―12 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 559 |
[GO] |
2022―Aug―12 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 560 |
[GO] |
2022―Aug―06 |
Covid-19 vaccine |
|
| 561 |
[GO] |
2022―Aug―06 |
COVID-19-vaccine |
|
| 562 |
[GO] |
2022―Jul―29 |
Safety of COVID-19 mRNA vaccine first booster doses among immunocompromised persons |
|
| 563 |
[GO] |
2022―Jul―29 |
COVID-19 vaccination: reports of Bell's palsy |
|
| 564 |
[GO] |
2022―Jul―29 |
COVID-19 vaccine |
|
| 565 |
[GO] |
2022―Jul―29 |
COVID-19 vaccine: risk of increased menstrual bleeding |
|
| 566 |
[GO] |
2022―Jul―29 |
COVID-19-vaccine |
|
| 567 |
[GO] |
2022―Jul―29 |
COVID-19-vaccine/ipilimumab/nivolumab |
|
| 568 |
[GO] |
2022―Jul―29 |
COVID-19-vaccines |
|
| 569 |
[GO] |
2022―Jul―23 |
Covid-19-vaccine |
|
| 570 |
[GO] |
2022―Jul―23 |
COVID-19-vaccine |
|
| 571 |
[GO] |
2022―Jul―23 |
Sars-cov-2 vaccine inactivated Sinovac Biotech/tozinameran |
|
| 572 |
[GO] |
2022―Jul―15 |
Covid-19 vaccine |
|
| 573 |
[GO] |
2022―Jul―15 |
Active surveillance confirms short-term safety of COVID-19 vaccines in Australia |
|
| 574 |
[GO] |
2022―Jul―15 |
COVID-19 vaccines: reports of lichen planus |
|
| 575 |
[GO] |
2022―Jul―15 |
Covid-19-vaccine |
|
| 576 |
[GO] |
2022―Jul―15 |
Covid-19-vaccine |
|
| 577 |
[GO] |
2022―Jul―15 |
Covid-19-vaccine |
|
| 578 |
[GO] |
2022―Jul―15 |
COVID-19-vaccine |
|
| 579 |
[GO] |
2022―Jul―15 |
Covid-19-vaccine-pfizer-biontech/elasomeran |
|
| 580 |
[GO] |
2022―Jul―15 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 581 |
[GO] |
2022―Jul―08 |
Myocarditis/pericarditis rare after COVID-19 mRNA vaccination |
|
| 582 |
[GO] |
2022―Jul―08 |
Covid-19 vaccine pfizer biontech |
|
| 583 |
[GO] |
2022―Jul―08 |
Covid-19 vaccine pfizer biontech |
|
| 584 |
[GO] |
2022―Jul―08 |
Covid-19-vaccine |
|
| 585 |
[GO] |
2022―Jul―08 |
Covid-19-vaccine |
|
| 586 |
[GO] |
2022―Jul―08 |
COVID-19-vaccine |
|
| 587 |
[GO] |
2022―Jul―08 |
SARS-COV-2-vaccine inactivated Sinovac Biotech |
|
| 588 |
[GO] |
2022―Jul―08 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 589 |
[GO] |
2022―Jul―08 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech/tozinameran |
|
| 590 |
[GO] |
2022―Jul―01 |
Covid-19 vaccine |
|
| 591 |
[GO] |
2022―Jul―01 |
COVID-19 vaccine Pfizer BioNTech |
|
| 592 |
[GO] |
2022―Jul―01 |
Signal detection of COVID-19 vaccine-related AEs |
|
| 593 |
[GO] |
2022―Jul―01 |
COVID-19-vaccine |
|
| 594 |
[GO] |
2022―Jul―01 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 595 |
[GO] |
2022―Jul―01 |
Covid-19-vaccine-Pfizer-BioNTech |
|
| 596 |
[GO] |
2022―Jul―01 |
Covid-19-vaccine-pfizer-biontech |
|
| 597 |
[GO] |
2022―Jul―01 |
Covid-19-vaccine-pfizer-biontech |
|
| 598 |
[GO] |
2022―Jul―01 |
Covid-19-vaccine-pfizer-biontech |
|
| 599 |
[GO] |
2022―Jul―01 |
COVID-19-vaccine-Pfizer-Biontech/elasomeran |
|
| 600 |
[GO] |
2022―Jul―01 |
Covid-19-vaccine-pfizer-biontech/olanzapine/tetrabenazine |
|
| 601 |
[GO] |
2022―Jul―01 |
COVID-19-vaccines/immunosuppressants |
|
| 602 |
[GO] |
2022―Jul―01 |
SARS-CoV-2 vaccine inactivated Sinovac Biotech |
|
| 603 |
[GO] |
2022―Jul―01 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 604 |
[GO] |
2022―Jun―23 |
Acute neurological AEs after COVID-19 vaccination |
|
| 605 |
[GO] |
2022―Jun―23 |
COVID-19 vaccination and risk of neuralgic amyotrophy |
|
| 606 |
[GO] |
2022―Jun―23 |
COVID-19 vaccination relatively safe in autoimmune diseases |
|
| 607 |
[GO] |
2022―Jun―23 |
COVID-19 vaccines/mycophenolate mofetil |
|
| 608 |
[GO] |
2022―Jun―23 |
Sars-cov-2-vaccine-inactivated |
|
| 609 |
[GO] |
2022―Jun―23 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 610 |
[GO] |
2022―Jun―23 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 611 |
[GO] |
2022―Jun―23 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 612 |
[GO] |
2022―Jun―17 |
Risk of myocarditis or pericarditis after COVID-19 mRNA vaccines |
|
| 613 |
[GO] |
2022―Jun―17 |
Risk of Guillain-Barre Syndrome after COVID-19 vaccination |
|
| 614 |
[GO] |
2022―Jun―17 |
Janssen COVID-19 vaccine increases risk of thrombocytopenia |
|
| 615 |
[GO] |
2022―Jun―17 |
COVID-19 vaccine-Pfizer-BioNTech |
|
| 616 |
[GO] |
2022―Jun―17 |
Covid-19-vaccine first report |
|
| 617 |
[GO] |
2022―Jun―17 |
Covid-19-vaccine-pfizer-biontech |
|
| 618 |
[GO] |
2022―Jun―17 |
SARS-COV-2-vaccine-inactivated Sinovac-Biotech |
|
| 619 |
[GO] |
2022―Jun―17 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 620 |
[GO] |
2022―Jun―17 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 621 |
[GO] |
2022―Jun―10 |
AEs after homologous versus heterologous COVID-19 booster |
|
| 622 |
[GO] |
2022―Jun―10 |
Standardised assessment of COVID-19 vaccine-related skin reactions |
|
| 623 |
[GO] |
2022―Jun―10 |
Safety of mRNA COVID-19 vaccines during pregnancy |
|
| 624 |
[GO] |
2022―Jun―10 |
Covid-19-vaccine/lamotrigine |
|
| 625 |
[GO] |
2022―Jun―03 |
Low risk of myopericarditis after COVID-19 vaccination in children aged 5-11 years |
|
| 626 |
[GO] |
2022―Jun―03 |
Pfizer-BioNTech COVID-19 vaccine safe with clozapine |
|
| 627 |
[GO] |
2022―Jun―03 |
COVID-19 vaccine-induced VITT/TSS in Malaysia |
|
| 628 |
[GO] |
2022―Jun―03 |
Lareb study on COVID-19 vaccine-related menstrual disorders |
|
| 629 |
[GO] |
2022―Jun―03 |
COVID-19-vaccine |
|
| 630 |
[GO] |
2022―Jun―03 |
COVID-19-vaccine |
|
| 631 |
[GO] |
2022―Jun―03 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 632 |
[GO] |
2022―Jun―03 |
Covid-19-vaccine-pfizer-biontech |
|
| 633 |
[GO] |
2022―Jun―03 |
COVID-19-vaccine-Pfizer-BioNtech |
|
| 634 |
[GO] |
2022―Jun―03 |
COVID-19-vaccine/SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
| 635 |
[GO] |
2022―Jun―03 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 636 |
[GO] |
2022―Jun―03 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 637 |
[GO] |
2022―Jun―03 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
| 638 |
[GO] |
2022―Mai―27 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 639 |
[GO] |
2022―Mai―27 |
Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated |
|
| 640 |
[GO] |
2022―Mai―27 |
Pfizer-BioNTech COVID-19 vaccine safe in children |
|
| 641 |
[GO] |
2022―Mai―27 |
Covid-19-vaccine |
|
| 642 |
[GO] |
2022―Mai―27 |
Covid-19-vaccine |
|
| 643 |
[GO] |
2022―Mai―27 |
Covid-19-vaccine |
|
| 644 |
[GO] |
2022―Mai―27 |
Covid-19-vaccine-pfizer-biontech |
|
| 645 |
[GO] |
2022―Mai―27 |
Covid-19-vaccine-pfizer-biontech/elasomeran |
|
| 646 |
[GO] |
2022―Mai―20 |
ADRs due to off-label use of hydroxychloroquine for COVID-19 |
|
| 647 |
[GO] |
2022―Mai―20 |
Survey of adverse events following ChAdOx1 COVID-19 vaccination in Ethiopia |
|
| 648 |
[GO] |
2022―Mai―20 |
COVID-19-vaccine |
|
| 649 |
[GO] |
2022―Mai―20 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/immunosuppressants |
|
| 650 |
[GO] |
2022―Mai―20 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 651 |
[GO] |
2022―Mai―20 |
Covid-19-vaccine-pfizer-biontech |
|
| 652 |
[GO] |
2022―Mai―20 |
Covid-19-vaccine-pfizer-biontech/levothyroxine-sodium/sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 653 |
[GO] |
2022―Mai―20 |
COVID-19-vaccines/budesonide/mesalazine |
|
| 654 |
[GO] |
2022―Mai―13 |
FDA limits authorised use of Janssen COVID-19 vaccine |
|
| 655 |
[GO] |
2022―Mai―13 |
Covid-19-vaccine-pfizer-biontech |
|
| 656 |
[GO] |
2022―Mai―13 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 657 |
[GO] |
2022―Mai―13 |
Covid-19-vaccine-pfizer-biontech |
|
| 658 |
[GO] |
2022―Mai―13 |
COVID-19-vaccine/plasma |
|
| 659 |
[GO] |
2022―Mai―13 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 660 |
[GO] |
2022―Mai―06 |
COVID-19 vaccination may reactivate varicella-zoster virus |
|
| 661 |
[GO] |
2022―Mai―06 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 662 |
[GO] |
2022―Mai―06 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 663 |
[GO] |
2022―Apr―29 |
No increased risk for venous thromboembolism after COVID-19 vaccination |
|
| 664 |
[GO] |
2022―Apr―29 |
Safety profile of mRNA vaccines during first 6 months of the US COVID-19 vaccination programme reviewed |
|
| 665 |
[GO] |
2022―Apr―29 |
COVID-19 vaccine Gamaleya National Research Center of Epidemiology and Microbiology |
|
| 666 |
[GO] |
2022―Apr―29 |
COVID-19 Vaccine Pfizer BioNTech |
|
| 667 |
[GO] |
2022―Apr―29 |
Covid-19-vaccine |
|
| 668 |
[GO] |
2022―Apr―29 |
COVID-19-Vaccine-Pfizer-BioNTech/pegfilgrastim/pembrolizumab |
|
| 669 |
[GO] |
2022―Apr―29 |
Covid-19-vaccine/methylprednisolone |
|
| 670 |
[GO] |
2022―Apr―29 |
COVID-19-vaccine/mycophenolate |
|
| 671 |
[GO] |
2022―Apr―22 |
Cardiac risks higher after COVID-19 infection than mRNA vaccine |
|
| 672 |
[GO] |
2022―Apr―22 |
Lopinavir/ritonavir delays COVID-19 recovery in paediatric patients |
|
| 673 |
[GO] |
2022―Apr―22 |
PRAC meeting highlights April 2022: no link between mRNA COVID-19 vaccines and autoimmune hepatitis |
|
| 674 |
[GO] |
2022―Apr―22 |
Covid-19-vaccine |
|
| 675 |
[GO] |
2022―Apr―22 |
Covid-19-vaccine-pfizer-biontech |
|
| 676 |
[GO] |
2022―Apr―22 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 677 |
[GO] |
2022―Apr―22 |
COVID-19-Vaccine-Pfizer-BioNTech/elasomeran |
|
| 678 |
[GO] |
2022―Apr―22 |
Covid-19-vaccine-pfizer-biontech/prednisone/valaciclovir |
|
| 679 |
[GO] |
2022―Apr―22 |
COVID-19-vaccines/immune-globulin/methylprednisolone |
|
| 680 |
[GO] |
2022―Apr―22 |
Coronavirus-vaccine |
|
| 681 |
[GO] |
2022―Apr―14 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology |
|
| 682 |
[GO] |
2022―Apr―14 |
Covid-19-vaccine-pfizer-biontech |
|
| 683 |
[GO] |
2022―Apr―14 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 684 |
[GO] |
2022―Apr―14 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 685 |
[GO] |
2022―Apr―08 |
Remdesivir does not increase risk of AKI or ALI in COVID-19 patients |
|
| 686 |
[GO] |
2022―Apr―08 |
COVID-19 vaccine-Pfizer-BioNTech/methylprednisolone aceponate |
|
| 687 |
[GO] |
2022―Apr―08 |
No evidence of adverse neurological outcomes from COVID-19 vaccines |
|
| 688 |
[GO] |
2022―Apr―08 |
Covid-19-vaccine |
|
| 689 |
[GO] |
2022―Apr―08 |
COVID-19-vaccine |
|
| 690 |
[GO] |
2022―Apr―08 |
Covid-19-vaccine |
|
| 691 |
[GO] |
2022―Apr―08 |
Covid-19-vaccine-pfizer-biontech |
|
| 692 |
[GO] |
2022―Apr―08 |
Covid-19-vaccine-pfizer-biontech |
|
| 693 |
[GO] |
2022―Apr―08 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 694 |
[GO] |
2022―Apr―08 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 695 |
[GO] |
2022―Apr―08 |
Covid-19-vaccine/evolocumab |
|
| 696 |
[GO] |
2022―Apr―08 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 697 |
[GO] |
2022―Apr―08 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 698 |
[GO] |
2022―Apr―01 |
No safety signal after COVID-19 vaccination for immune-mediated neurological events |
|
| 699 |
[GO] |
2022―Apr―01 |
Myocarditis after third dose of Pfizer-BioNTech COVID-19 vaccine |
|
| 700 |
[GO] |
2022―Apr―01 |
COVID-19-vaccine |
|
| 701 |
[GO] |
2022―Apr―01 |
Covid-19-vaccine |
|
| 702 |
[GO] |
2022―Apr―01 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 703 |
[GO] |
2022―Apr―01 |
Covid-19-vaccine-pfizer-biontech |
|
| 704 |
[GO] |
2022―Apr―01 |
Covid-19-vaccine-pfizer-biontech |
|
| 705 |
[GO] |
2022―Apr―01 |
Covid-19-vaccine-pfizer-biontech/ibuprofen/paracetamol/meloxicam |
|
| 706 |
[GO] |
2022―Apr―01 |
Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19? |
|
| 707 |
[GO] |
2022―Mrz―25 |
Systemic AEs common after COVID-19 vaccination |
|
| 708 |
[GO] |
2022―Mrz―25 |
COVID-19 vaccine Gamaleya National Research Center of Epidermiology and Microbiology |
|
| 709 |
[GO] |
2022―Mrz―25 |
Covid-19 vaccine-Pfizer-BioNtech |
|
| 710 |
[GO] |
2022―Mrz―25 |
Covid-19-vaccine |
|
| 711 |
[GO] |
2022―Mrz―25 |
Covid-19-vaccine-gamaleya-national-research-center-of-epidemiology-and-microbiology/fexofenadine |
|
| 712 |
[GO] |
2022―Mrz―25 |
Covid-19-vaccine-pfizer-biontech |
|
| 713 |
[GO] |
2022―Mrz―25 |
Covid-19-vaccine-pfizer-biontech |
|
| 714 |
[GO] |
2022―Mrz―25 |
Covid-19-vaccine-pfizer-biontech/sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 715 |
[GO] |
2022―Mrz―25 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 716 |
[GO] |
2022―Mrz―19 |
Covid-19-vaccine-pfizer-biontech |
|
| 717 |
[GO] |
2022―Mrz―19 |
COVID-19-Vaccine-Pfizer-BioNTech/elasomeran |
|
| 718 |
[GO] |
2022―Mrz―19 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 719 |
[GO] |
2022―Mrz―19 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 720 |
[GO] |
2022―Mrz―19 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 721 |
[GO] |
2022―Mrz―11 |
Covid-19-vaccine-pfizer-biontech |
|
| 722 |
[GO] |
2022―Mrz―11 |
Covid-19-vaccine-pfizer-biontech/elasomeran |
|
| 723 |
[GO] |
2022―Mrz―11 |
Coronavirus-vaccine |
|
| 724 |
[GO] |
2022―Mrz―11 |
Coronavirus-vaccine-stemirna-therapeutics/tongji-university |
|
| 725 |
[GO] |
2022―Mrz―05 |
Health Canada: risk of accidental poisoning from COVID-19 rapid antigen test kits |
|
| 726 |
[GO] |
2022―Mrz―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 727 |
[GO] |
2022―Mrz―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 728 |
[GO] |
2022―Mrz―05 |
COVID-19-vaccine-pfizer-biontech |
|
| 729 |
[GO] |
2022―Mrz―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 730 |
[GO] |
2022―Mrz―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 731 |
[GO] |
2022―Mrz―05 |
Covid-19-vaccine-pfizer-biontech |
|
| 732 |
[GO] |
2022―Mrz―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 733 |
[GO] |
2022―Mrz―05 |
Covid-19-vaccine-pfizer-biontech |
|
| 734 |
[GO] |
2022―Mrz―05 |
Covid-19-vaccine-pfizer-biontech/omalizumab |
|
| 735 |
[GO] |
2022―Mrz―05 |
Covid-19-vaccine/vildagliptin interaction |
|
| 736 |
[GO] |
2022―Mrz―05 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
| 737 |
[GO] |
2022―Feb―25 |
COVID-19 vaccine |
|
| 738 |
[GO] |
2022―Feb―25 |
COVID-19 vaccine |
|
| 739 |
[GO] |
2022―Feb―25 |
COVID-19 vaccine |
|
| 740 |
[GO] |
2022―Feb―25 |
Covid-19-vaccine |
|
| 741 |
[GO] |
2022―Feb―25 |
Covid-19-vaccine-pfizer-biontech |
|
| 742 |
[GO] |
2022―Feb―25 |
Covid-19-vaccine-pfizer-biontech |
|
| 743 |
[GO] |
2022―Feb―25 |
COVID-19-Vaccine-Pfizer-BioNTech/epinephrine |
|
| 744 |
[GO] |
2022―Feb―18 |
Increase in thromboembolic ADRs from oral contraceptives during COVID-19 pandemic in Spain |
|
| 745 |
[GO] |
2022―Feb―18 |
No adverse effects found for prenatal exposure to mRNA COVID-19 vaccine |
|
| 746 |
[GO] |
2022―Feb―18 |
COVID-19 Vaccine Pfizer BioNTech |
|
| 747 |
[GO] |
2022―Feb―18 |
COVID-19 Vaccine Pfizer BioNTech |
|
| 748 |
[GO] |
2022―Feb―18 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 749 |
[GO] |
2022―Feb―18 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 750 |
[GO] |
2022―Feb―18 |
Coronavirus-vaccine |
|
| 751 |
[GO] |
2022―Feb―18 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 752 |
[GO] |
2022―Feb―11 |
mRNA COVID-19 vaccines safe in patients with previous COVID-19 infections |
|
| 753 |
[GO] |
2022―Feb―11 |
COVID-19 vaccine errors dominate ISMP's list of top 10 safety concerns for 2021 |
|
| 754 |
[GO] |
2022―Feb―11 |
Covid-19-vaccine-pfizer-biontech |
|
| 755 |
[GO] |
2022―Feb―11 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 756 |
[GO] |
2022―Feb―11 |
Covid-19-vaccine-pfizer-biontech |
|
| 757 |
[GO] |
2022―Feb―11 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 758 |
[GO] |
2022―Feb―11 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 759 |
[GO] |
2022―Feb―11 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 760 |
[GO] |
2022―Feb―11 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 761 |
[GO] |
2022―Feb―04 |
Younger males at greatest risk of myocarditis after mRNA-based COVID-19 vaccination |
|
| 762 |
[GO] |
2022―Feb―04 |
COVID-19 vaccine |
|
| 763 |
[GO] |
2022―Feb―04 |
Growing evidence reassuring for mRNA COVID-19 vaccines in pregnancy |
|
| 764 |
[GO] |
2022―Feb―04 |
COVID-19-vaccine |
|
| 765 |
[GO] |
2022―Feb―04 |
Covid-19-vaccine |
|
| 766 |
[GO] |
2022―Feb―04 |
Covid-19-vaccine |
|
| 767 |
[GO] |
2022―Jan―28 |
Reported rates of CVST due to COVID-19 vaccination rose after publicising these ADRs |
|
| 768 |
[GO] |
2022―Jan―28 |
Ad26.COV2.S COVID-19 vaccine: TTS a rare, but serious adverse event |
|
| 769 |
[GO] |
2022―Jan―28 |
Covid-19-vaccine-pfizer-biontech |
|
| 770 |
[GO] |
2022―Jan―28 |
Covid-19-vaccine-pfizer-biontech |
|
| 771 |
[GO] |
2022―Jan―28 |
Covid-19-vaccine-pfizer-biontech |
|
| 772 |
[GO] |
2022―Jan―28 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 773 |
[GO] |
2022―Jan―28 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 774 |
[GO] |
2022―Jan―28 |
Coronavirus-vaccine |
|
| 775 |
[GO] |
2022―Jan―28 |
Coronavirus-vaccine |
|
| 776 |
[GO] |
2022―Jan―21 |
COVID-19 vaccines safe in people living with HIV |
|
| 777 |
[GO] |
2022―Jan―21 |
SARS-COV-2 vaccine inactivated Sinovac Biotech |
|
| 778 |
[GO] |
2022―Jan―21 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 779 |
[GO] |
2022―Jan―21 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 780 |
[GO] |
2022―Jan―21 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 781 |
[GO] |
2022―Jan―14 |
Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant |
|
| 782 |
[GO] |
2022―Jan―14 |
Rare reports of rheumatic disorder flares after COVID-19 vaccination |
|
| 783 |
[GO] |
2022―Jan―14 |
Small change in menstrual cycle length after COVID-19 vaccination |
|
| 784 |
[GO] |
2022―Jan―14 |
Expected rates of adverse events after COVID-19 vaccination in USA |
|
| 785 |
[GO] |
2022―Jan―14 |
Covid-19-vaccine/tozinameran |
|
| 786 |
[GO] |
2022―Jan―14 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech/tozinameran |
|
| 787 |
[GO] |
2022―Jan―06 |
Low rate of myocarditis/pericarditis after COVID-19 mRNA vaccines |
|
| 788 |
[GO] |
2022―Jan―06 |
COVID-19 Vaccine Pfizer BioNTech |
|
| 789 |
[GO] |
2022―Jan―06 |
Signal for COVID-19 vaccine-related menstrual disorders |
|
| 790 |
[GO] |
2022―Jan―06 |
Systematic review: COVID-19 vaccine-related neurological disorders "exceedingly" rare |
|
| 791 |
[GO] |
2022―Jan―06 |
COVID-19-vaccine |
|
| 792 |
[GO] |
2022―Jan―06 |
COVID-19-vaccine |
|
| 793 |
[GO] |
2022―Jan―06 |
COVID-19-vaccine |
|
| 794 |
[GO] |
2022―Jan―06 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
| 795 |
[GO] |
2022―Jan―06 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 796 |
[GO] |
2022―Jan―06 |
Covid-19-vaccine-pfizer-biontech |
|
| 797 |
[GO] |
2022―Jan―06 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 798 |
[GO] |
2022―Jan―06 |
Covid-19-vaccine-pfizer-biontech |
|
| 799 |
[GO] |
2022―Jan―06 |
Covid-19-vaccine-pfizer-biontech |
|
| 800 |
[GO] |
2022―Jan―06 |
Covid-19-vaccine/influenza-virus-vaccine |
|
| 801 |
[GO] |
2022―Jan―06 |
Covid-19-vaccine/mrna-1273 |
|
| 802 |
[GO] |
2022―Jan―06 |
SARS-COV-2 vaccine inactivated-Sinovac-Biotech |
|
| 803 |
[GO] |
2022―Jan―06 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 804 |
[GO] |
2022―Jan―06 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 805 |
[GO] |
2022―Jan―06 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 806 |
[GO] |
2021―Dez―18 |
COVID-19 Vaccine Pfizer-BioNTech |
|
| 807 |
[GO] |
2021―Dez―18 |
Most adolescent myocarditis cases related to covid-19 vaccines mild, resolve quickly |
|
| 808 |
[GO] |
2021―Dez―18 |
Covid-19-vaccine-pfizer-biontech |
|
| 809 |
[GO] |
2021―Dez―18 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 810 |
[GO] |
2021―Dez―18 |
Coronavirus vaccine |
|
| 811 |
[GO] |
2021―Dez―18 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 812 |
[GO] |
2021―Dez―18 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 813 |
[GO] |
2021―Dez―10 |
Safety of seven COVID-19 vaccine booster doses |
|
| 814 |
[GO] |
2021―Dez―10 |
Myocarditis, pericarditis with COVID-19 vaccines in the Netherlands |
|
| 815 |
[GO] |
2021―Dez―10 |
COVID-19 vaccines/rituximab |
|
| 816 |
[GO] |
2021―Dez―10 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 817 |
[GO] |
2021―Dez―10 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 818 |
[GO] |
2021―Dez―10 |
Covid-19-vaccine/immune-globulin/methylprednisolone |
|
| 819 |
[GO] |
2021―Dez―10 |
COVID-19-vaccines |
|
| 820 |
[GO] |
2021―Dez―10 |
Covid-19-vaccines/rituximab |
|
| 821 |
[GO] |
2021―Dez―10 |
Sars-cov-2-vaccine-inactivated-sinovac-biotech |
|
| 822 |
[GO] |
2021―Dez―10 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 823 |
[GO] |
2021―Dez―04 |
Risk-benefit of AstraZeneca COVID-19 vaccination in Australia |
|
| 824 |
[GO] |
2021―Dez―04 |
No increase in stroke, MI or PE after Pfizer-BioNTech COVID-19 vaccine |
|
| 825 |
[GO] |
2021―Dez―04 |
Adverse reactions with Pfizer/BioNTech's COVID-19 vaccine in Ecuador |
|
| 826 |
[GO] |
2021―Dez―04 |
Pfizer-BioNTech COVID-19 vaccine safe in older Koreans |
|
| 827 |
[GO] |
2021―Dez―04 |
COVID-19-vaccine |
|
| 828 |
[GO] |
2021―Dez―04 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 829 |
[GO] |
2021―Dez―04 |
Covid-19-vaccine-pfizer-biontech |
|
| 830 |
[GO] |
2021―Dez―04 |
Covid-19-vaccine-pfizer-biontech |
|
| 831 |
[GO] |
2021―Dez―04 |
COVID-19-Vaccine-Pfizer-BioNTech/mRNA-1273 |
|
| 832 |
[GO] |
2021―Dez―04 |
Coronavirus-vaccine |
|
| 833 |
[GO] |
2021―Dez―04 |
Coronavirus-vaccine-Wuhan-Institute-of-Biological-Products |
|
| 834 |
[GO] |
2021―Nov―26 |
Cutaneous vasculitis following COVID-19 vaccination |
|
| 835 |
[GO] |
2021―Nov―26 |
COVID-19 vaccine Pfizer BioNTech |
|
| 836 |
[GO] |
2021―Nov―26 |
Possibility of mix-up with paediatric COVID-19 vaccines |
|
| 837 |
[GO] |
2021―Nov―26 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 838 |
[GO] |
2021―Nov―26 |
Covid-19-vaccine-pfizer-biontech |
|
| 839 |
[GO] |
2021―Nov―26 |
Covid-19-vaccine-pfizer-biontech |
|
| 840 |
[GO] |
2021―Nov―19 |
Myocarditis rare after COVID-19 mRNA vaccination |
|
| 841 |
[GO] |
2021―Nov―19 |
Increased risk of immune thrombocytopenia following AstraZeneca Covid-19 vaccine |
|
| 842 |
[GO] |
2021―Nov―19 |
English-only labels for Janssen's COVID-19 vaccine in Canada |
|
| 843 |
[GO] |
2021―Nov―19 |
COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology |
|
| 844 |
[GO] |
2021―Nov―19 |
Covid-19-vaccine-pfizer-biontech |
|
| 845 |
[GO] |
2021―Nov―19 |
Covid-19-vaccine-pfizer-biontech |
|
| 846 |
[GO] |
2021―Nov―19 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 847 |
[GO] |
2021―Nov―19 |
Covid-19-vaccine-pfizer-biontech |
|
| 848 |
[GO] |
2021―Nov―19 |
COVID-19-vaccine-pfizer-biontech/ibuprofen/oxycodone |
|
| 849 |
[GO] |
2021―Nov―19 |
Covid-19-vaccine-Pfizer-BioNTech/mRNA-1273 |
|
| 850 |
[GO] |
2021―Nov―05 |
COVID-19 vaccine |
|
| 851 |
[GO] |
2021―Nov―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 852 |
[GO] |
2021―Nov―05 |
Covid-19-vaccine-pfizer-biontech |
|
| 853 |
[GO] |
2021―Nov―05 |
Covid-19-vaccine-pfizer-biontech |
|
| 854 |
[GO] |
2021―Nov―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 855 |
[GO] |
2021―Nov―05 |
Covid-19-vaccine-pfizer-biontech |
|
| 856 |
[GO] |
2021―Nov―05 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 857 |
[GO] |
2021―Nov―05 |
COVID-19-Vaccine-Pfizer-BioNTech/mRNA-1273 |
|
| 858 |
[GO] |
2021―Nov―05 |
COVID-19-Vaccine-Pfizer-BioNTech/mycophenolic acid/tacrolimus |
|
| 859 |
[GO] |
2021―Nov―05 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 860 |
[GO] |
2021―Okt―29 |
Covid-19-vaccine-pfizer-biontech |
|
| 861 |
[GO] |
2021―Okt―29 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 862 |
[GO] |
2021―Okt―29 |
Covid-19-vaccine/rituximab |
|
| 863 |
[GO] |
2021―Okt―22 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 864 |
[GO] |
2021―Okt―22 |
Covid-19-vaccine-pfizer-biontech |
|
| 865 |
[GO] |
2021―Okt―22 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 866 |
[GO] |
2021―Okt―22 |
Covid-19-vaccine-pfizer-biontech |
|
| 867 |
[GO] |
2021―Okt―22 |
Covid-19-vaccine-pfizer-biontech |
|
| 868 |
[GO] |
2021―Okt―22 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 869 |
[GO] |
2021―Okt―22 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 870 |
[GO] |
2021―Okt―22 |
Janssen/Johnson & Johnson COVID-19 vaccine-related GBS in USA |
|
| 871 |
[GO] |
2021―Okt―22 |
Myocarditis with Pfizer-BioNTech's COVID-19 vaccine in Israel |
|
| 872 |
[GO] |
2021―Okt―22 |
COVID-19 vaccine and influenza vaccine mix-ups |
|
| 873 |
[GO] |
2021―Okt―22 |
COVID-19 vaccine |
|
| 874 |
[GO] |
2021―Okt―22 |
Coronavirus-vaccine |
|
| 875 |
[GO] |
2021―Okt―16 |
Pfizer-BioNTech COVID-19 vaccine in patients with severe allergies |
|
| 876 |
[GO] |
2021―Okt―16 |
Covid-19-vaccine |
|
| 877 |
[GO] |
2021―Okt―16 |
COVID-19-vaccine |
|
| 878 |
[GO] |
2021―Okt―16 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 879 |
[GO] |
2021―Okt―16 |
SARS-COV-2 vaccine inactivated Sinovac Biotech |
|
| 880 |
[GO] |
2021―Okt―16 |
No evidence of birth defects or spontaneous abortion from pandemic H1N1-influenza vaccine |
|
| 881 |
[GO] |
2021―Okt―10 |
Covid-19 vaccine-Pfizer-Biontech |
|
| 882 |
[GO] |
2021―Okt―10 |
No association between COVID-19 vaccination and menstrual disorders |
|
| 883 |
[GO] |
2021―Okt―01 |
FAPIC score predicts mortality after COVID-19 vaccine-related TTS |
|
| 884 |
[GO] |
2021―Okt―01 |
Product monographs for COVID-19 vaccines updated in Canada |
|
| 885 |
[GO] |
2021―Okt―01 |
Covid-19-vaccine-pfizer-biontech |
|
| 886 |
[GO] |
2021―Okt―01 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 887 |
[GO] |
2021―Sep―24 |
COVID-19 vaccination safe during pregnancy |
|
| 888 |
[GO] |
2021―Sep―24 |
Covid-19-vaccine-pfizer-biontech |
|
| 889 |
[GO] |
2021―Sep―17 |
Minimal risk of GBS relapse after Pfizer-BioNTech COVID-19 vaccination |
|
| 890 |
[GO] |
2021―Sep―17 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 891 |
[GO] |
2021―Sep―17 |
COVID-19-Vaccine-Pfizer-BioNTech/ciclosporin/mycophenolate sodium |
|
| 892 |
[GO] |
2021―Sep―17 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 893 |
[GO] |
2021―Sep―12 |
Warnings of risks associated with ivermectin use for COVID-19 |
|
| 894 |
[GO] |
2021―Sep―12 |
mRNA-based vs viral vector-based COVID-19 vaccines |
|
| 895 |
[GO] |
2021―Sep―12 |
Covid-19-vaccine-pfizer-biontech |
|
| 896 |
[GO] |
2021―Sep―12 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 897 |
[GO] |
2021―Sep―12 |
Coronavirus-vaccine-stemirna-therapeutics/tongji-university |
|
| 898 |
[GO] |
2021―Sep―12 |
SARS-COV-2-vaccine-inactivated-Sinovac-Biotech |
|
| 899 |
[GO] |
2021―Sep―04 |
Antihypertensives: sex differences in risk of COVID-19 |
|
| 900 |
[GO] |
2021―Sep―04 |
Thrombocytopenia and thromboembolism after COVID-19 vaccination |
|
| 901 |
[GO] |
2021―Sep―04 |
COVID-19 Vaccine Pfizer BioNTech |
|
| 902 |
[GO] |
2021―Sep―04 |
AstraZeneca COVID-19 vaccine-related thrombocytopenia and thrombosis |
|
| 903 |
[GO] |
2021―Sep―04 |
Covid-19-vaccine-Pfizer-BioNTech |
|
| 904 |
[GO] |
2021―Sep―04 |
Covid-19-vaccine-pfizer-biontech |
|
| 905 |
[GO] |
2021―Sep―04 |
Covid-19-vaccine-pfizer-biontech |
|
| 906 |
[GO] |
2021―Sep―04 |
Convalescent anti SARS-CoV-2 plasma/norepinephrine/tocilizumab |
|
| 907 |
[GO] |
2021―Aug―27 |
Covid-19 vaccine pfizer biontech |
|
| 908 |
[GO] |
2021―Aug―27 |
Teen COVE study finds Moderna COVID-19 vaccine safe in adolescents |
|
| 909 |
[GO] |
2021―Aug―27 |
Janssen COVID-19 vaccine-related tinnitus and dizziness |
|
| 910 |
[GO] |
2021―Aug―27 |
Covid-19-vaccine-Pfizer-BioNTech |
|
| 911 |
[GO] |
2021―Aug―21 |
COVID-19 vaccination encouraged by the EMA/ECDC |
|
| 912 |
[GO] |
2021―Aug―21 |
Pfizer-BioNTech COVID-19 vaccine label update on Bell's palsy in Canada |
|
| 913 |
[GO] |
2021―Aug―21 |
Cerebral vein thrombosis after four COVID-19 vaccines in Europe |
|
| 914 |
[GO] |
2021―Aug―21 |
Covid-19-vaccine-pfizer-biontech |
|
| 915 |
[GO] |
2021―Aug―21 |
Covid-19-vaccine-Pfizer-BioNTech/prednisone |
|
| 916 |
[GO] |
2021―Aug―21 |
Remdesivir vs tocilizumab in COVID-19: adverse event profiles |
|
| 917 |
[GO] |
2021―Aug―13 |
NSAIDs do not increase risk or severity of COVID-19 infections |
|
| 918 |
[GO] |
2021―Aug―13 |
Cerebral venous sinus thrombosis after COVID-19 vaccination |
|
| 919 |
[GO] |
2021―Aug―13 |
Anaphylaxis after Pfizer-BioNTech COVID-19 vaccine in Japan |
|
| 920 |
[GO] |
2021―Aug―13 |
PRAC meeting 5 August 2021: COVID-19 vaccine safety issues |
|
| 921 |
[GO] |
2021―Aug―13 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 922 |
[GO] |
2021―Aug―13 |
Covid-19-vaccine-pfizer-biontech |
|
| 923 |
[GO] |
2021―Aug―13 |
Covid-19-Vaccine-Pfizer-Biontech |
|
| 924 |
[GO] |
2021―Aug―13 |
Covid-19-vaccine-pfizer-biontech/levofloxacin |
|
| 925 |
[GO] |
2021―Aug―09 |
WHO GACVS reviews cases of GBS after COVID-19 vaccination |
|
| 926 |
[GO] |
2021―Aug―09 |
Rolling review of COVID-19 vaccine Vidprevtyn by EMA |
|
| 927 |
[GO] |
2021―Aug―09 |
Revisions of precautions for COVID-19 vaccines and other drugs in Japan |
|
| 928 |
[GO] |
2021―Aug―09 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 929 |
[GO] |
2021―Aug―09 |
Covid-19-vaccine-pfizer-biontech |
|
| 930 |
[GO] |
2021―Aug―01 |
EMA assessing safety of anakinra in adults with COVID-19 |
|
| 931 |
[GO] |
2021―Aug―01 |
PMDA: precautions should be revised for Covid-19 vaccine |
|
| 932 |
[GO] |
2021―Jul―23 |
Warning for Janssen COVID-19 vaccine: risk of Guillain-Barré syndrome |
|
| 933 |
[GO] |
2021―Jul―23 |
PRAC meeting highlights July 2021: Zynteglo and COVID-19 vaccines |
|
| 934 |
[GO] |
2021―Jul―23 |
COVID-19-Vaccine-Pfizer-BioNTech |
|
| 935 |
[GO] |
2021―Jul―23 |
Covid-19-vaccine-pfizer-biontech |
|
| 936 |
[GO] |
2021―Jul―17 |
AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome |
|
| 937 |
[GO] |
2021―Jul―05 |
Myocarditis or pericarditis following COVID-19 vaccination |
|
| 938 |
[GO] |
2021―Jul―05 |
Thrombocytopenic purpura with AstraZeneca but not Pfizer-BioNTech COVID-19 vaccine |
|
| 939 |
[GO] |
2021―Jul―05 |
COVID-19-vaccine-pfizer-biontech |
|
| 940 |
[GO] |
2021―Jul―05 |
Covid-19-vaccines |
|
| 941 |
[GO] |
2021―Jun―26 |
FDA reports recall of Innova COVID-19 antigen rapid qualitative test |
|
| 942 |
[GO] |
2021―Jun―26 |
Myocarditis and pericarditis after COVID-19 vaccination |
|
| 943 |
[GO] |
2021―Jun―26 |
PRAC June 2021 meeting highlights: COVID-19 vaccine AEs |
|
| 944 |
[GO] |
2021―Jun―26 |
US-labelled supply of Moderna's COVID-19 vaccine in Cananda |
|
| 945 |
[GO] |
2021―Jun―18 |
Biological or targeted synthetic DMARDs increase COVID-19 severity |
|
| 946 |
[GO] |
2021―Jun―18 |
Pfizer-BioNtech's COVID-19 vaccine approved for younger adolescents |
|
| 947 |
[GO] |
2021―Jun―18 |
Safeguarding against use of contaminated COVID-19 Vaccine Janssen |
|
| 948 |
[GO] |
2021―Jun―18 |
Heterogeneity in potential COVID-19 vaccine-related AEs |
|
| 949 |
[GO] |
2021―Jun―18 |
EMA advice on COVID-19 vaccine-related thrombosis with thrombocytopenia |
|
| 950 |
[GO] |
2021―Jun―12 |
Nursing home resident deaths after Pfizer-BioNTech's COVID-19 vaccine |
|
| 951 |
[GO] |
2021―Jun―12 |
Many Danes with fever after COVID-19 vaccine would contact doctor |
|
| 952 |
[GO] |
2021―Jun―05 |
Methotrexate adversely affects immunogenicity to COVID-19 mRNA vaccines |
|
| 953 |
[GO] |
2021―Jun―05 |
Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines |
|
| 954 |
[GO] |
2021―Jun―05 |
COVID-19-Vaccine-Pfizer-BioNTech/ocrelizumab |
|
| 955 |
[GO] |
2021―Mai―28 |
Bleeding and clotting with AstraZeneca's COVID-19 vaccine |
|
| 956 |
[GO] |
2021―Mai―28 |
Updated advice on thrombosis with thrombocytopenia syndrome and use of COVID-19 Vaccine AstraZeneca |
|
| 957 |
[GO] |
2021―Mai―21 |
COVID-19 vaccination during pregnancy: no increase in placental lesions |
|
| 958 |
[GO] |
2021―Mai―21 |
PRAC May 2021 meeting highlights: COVID-19 vaccine AEs |
|
| 959 |
[GO] |
2021―Mai―21 |
Do NSAIDs increase the severity of COVID-19? |
|
| 960 |
[GO] |
2021―Mai―14 |
COVID-19 vaccination errors in USA reported to ISMP |
|
| 961 |
[GO] |
2021―Mai―14 |
TTS with Janssen's COVID-19 vaccine |
|
| 962 |
[GO] |
2021―Mai―14 |
Anxiety disorders with Janssen's COVID-19 vaccine |
|
| 963 |
[GO] |
2021―Mai―14 |
AstraZeneca COVID-19 vaccine-related thromboembolism |
|
| 964 |
[GO] |
2021―Mai―14 |
AstraZeneca and Pfizer-BioNTech COVID-19 vaccines: AEs in South Korea |
|
| 965 |
[GO] |
2021―Mai―07 |
No evidence of TTS risk with Pfizer/BioNTech's COVID-19 vaccine |
|
| 966 |
[GO] |
2021―Mai―07 |
FDA and CDC recommend resuming use of Janssen COVID-19 vaccine |
|
| 967 |
[GO] |
2021―Mai―07 |
COVID-19 vaccine adverse events reported via app |
|
| 968 |
[GO] |
2021―Mai―07 |
AstraZeneca COVID-19 vaccine recommended in ≥50s in Australia |
|
| 969 |
[GO] |
2021―Mai―07 |
New EMA/ECDC initiative for monitoring COVID-19 vaccines |
|
| 970 |
[GO] |
2021―Mai―03 |
PRAC: blood clots with Janssen's COVID-19 vaccine |
|
| 971 |
[GO] |
2021―Mai―03 |
Canadian findings on AstraZeneca COVID-19 Vaccine and COVISHIELD |
|
| 972 |
[GO] |
2021―Apr―23 |
FDA remote evaluation of drug manufacturing during COVID-19 |
|
| 973 |
[GO] |
2021―Apr―23 |
Health Canada: blood clots with AstraZeneca's COVID-19 vaccine |
|
| 974 |
[GO] |
2021―Apr―23 |
Denmark ceases roll out of AstraZeneca's COVID-19 vaccine |
|
| 975 |
[GO] |
2021―Apr―23 |
COVID-19 Vaccine Janssen: rare unusual blood clots, low platelets |
|
| 976 |
[GO] |
2021―Apr―23 |
PRAC: blood clots or capillary leak syndrome with COVID-19 vaccines |
|
| 977 |
[GO] |
2021―Apr―23 |
Health Canada: AKI or ARF with remdesivir for COVID-19? |
|
| 978 |
[GO] |
2021―Apr―16 |
Should cancer patients receiving ICIs received COVID-19 vaccination? |
|
| 979 |
[GO] |
2021―Apr―16 |
Pfizer-BioNTech COVID-19 vaccine: AEs after vaccination in New Zealand |
|
| 980 |
[GO] |
2021―Apr―16 |
AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia |
|
| 981 |
[GO] |
2021―Apr―10 |
Falsified COVID-19 vaccine recently identified in Mexico |
|
| 982 |
[GO] |
2021―Apr―10 |
AstraZeneca COVID-19 vaccine: EMA continues review of rare blood clots |
|
| 983 |
[GO] |
2021―Apr―10 |
AstraZeneca COVID-19 vaccine: no increased rate of VTE |
|
| 984 |
[GO] |
2021―Apr―02 |
No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine |
|
| 985 |
[GO] |
2021―Apr―02 |
Ongoing evaluation of COVID-19 Vaccine AstraZeneca-related blood clots |
|
| 986 |
[GO] |
2021―Apr―02 |
AstraZeneca COVID-19 vaccine not recommended in adults under 55 in Canada |
|
| 987 |
[GO] |
2021―Mrz―26 |
Universal COVID-19 vaccination cost saving unless anaphylaxis rate high |
|
| 988 |
[GO] |
2021―Mrz―26 |
Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine |
|
| 989 |
[GO] |
2021―Mrz―26 |
Benefits of COVID-19 Vaccine AstraZeneca outweigh risks of blood clots |
|
| 990 |
[GO] |
2021―Mrz―26 |
March 2021 PRAC meeting highlights include COVID-19 vaccine update |
|
| 991 |
[GO] |
2021―Mrz―26 |
COVID-19-vaccine-Pfizer-BioNTech |
|
| 992 |
[GO] |
2021―Mrz―19 |
COVID-19 mRNA vaccines: acute allergic reaction and anaphylaxis |
|
| 993 |
[GO] |
2021―Mrz―19 |
Reports of flu-like symptoms after COVID-19 vaccination |
|
| 994 |
[GO] |
2021―Mrz―19 |
EMA assessing cases of blood clots after AstraZeneca COVID-19 vaccine |
|
| 995 |
[GO] |
2021―Mrz―19 |
COVID-19 vaccine AE reports in Australia and New Zealand |
|
| 996 |
[GO] |
2021―Mrz―13 |
Vial and carton labelling updated for Moderna COVID-19 vaccine |
|
| 997 |
[GO] |
2021―Mrz―13 |
COVID-19 vaccine-related lymphadenopathy may affect breast screening |
|
| 998 |
[GO] |
2021―Feb―26 |
COVID-19 vaccine safety monitoring |
|
| 999 |
[GO] |
2021―Feb―19 |
Second HPRA safety update on COVID-19 vaccines |
|
| 1000 |
[GO] |
2021―Feb―12 |
MHRA Yellow Card reports on COVID-19 vaccine adverse reactions |
|
| 1001 |
[GO] |
2021―Feb―12 |
Safety update on COVID-19 vaccine Comirnaty finds no new concerns |
|
| 1002 |
[GO] |
2021―Feb―05 |
Withdrawal of ACEIs or ARBs in hospitalised patients with COVID-19 |
|
| 1003 |
[GO] |
2021―Feb―05 |
WHO considers Pfizer BioNTech COVID-19 vaccine safe in elderly |
|
| 1004 |
[GO] |
2021―Feb―05 |
HPRA safety update on BioNTech and Moderna COVID-19 vaccines |
|
| 1005 |
[GO] |
2021―Jan―29 |
Norway advised to assess the very frail prior to COVID-19 vaccination |
|
| 1006 |
[GO] |
2021―Jan―29 |
Moderna COVID-19 vaccine: 2.5 cases of anaphylaxis per million doses |
|
| 1007 |
[GO] |
2021―Jan―29 |
ISMP reports: errors or hazards with COVID-19 vaccines |
|
| 1008 |
[GO] |
2021―Jan―29 |
NSAID use does not increase risk of COVID-19-related death |
|
| 1009 |
[GO] |
2021―Jan―22 |
Deaths in frail patients after Pfizer/BioNTech COVID-19 vaccination |
|
| 1010 |
[GO] |
2021―Jan―22 |
Advice on COVID-19 vaccines approved in UK by MHRA |
|
| 1011 |
[GO] |
2021―Jan―22 |
Safety of COVID-19 vaccines: who should see an allergist |
|
| 1012 |
[GO] |
2021―Jan―21 |
Pfizer-BioNTech COVID-19 vaccine-related risk of anaphylaxis |
|
| 1013 |
[GO] |
2021―Jan―08 |
Pfizer COVID-19-related drug use and safety surveillance |
|
| 1014 |
[GO] |
2021―Jan―06 |
Managing allergic reactions to Pfizer-BioNTech COVID-19 vaccine |
|
| 1015 |
[GO] |
2020―Dez―21 |
COVID-19-related deaths not increased with ACE inhibitor or ARB use |
|
| 1016 |
[GO] |
2020―Dez―11 |
EMA and ICMRA urge continuation of COVID-19 vaccine safety trials |
|
| 1017 |
[GO] |
2020―Nov―27 |
EMA's safety monitoring plan for COVID-19 vaccines |
|
| 1018 |
[GO] |
2020―Nov―20 |
Drug-drug interactions in patients with COVID-19 |
|
| 1019 |
[GO] |
2020―Nov―13 |
EMA guidance on risk management plans for COVID-19 vaccines reviewed |
|
| 1020 |
[GO] |
2020―Nov―06 |
Quality of ADR reporting evaluated for remdesivir trials of COVID-19 |
|
| 1021 |
[GO] |
2020―Nov―06 |
Hydroxychloroquine-related psychiatric disorders in COVID-19 patients |
|
| 1022 |
[GO] |
2020―Nov―06 |
Phase III trial of Covid-19 treatment paused for safety concerns |
|
| 1023 |
[GO] |
2020―Nov―06 |
Concerns raised with MHRA of anticoagulant use during pandemic |
|
| 1024 |
[GO] |
2020―Okt―16 |
Remdesivir-related acute kidney injury in patients with COVID-19 |
|
| 1025 |
[GO] |
2020―Okt―02 |
Sex differences in ADR reports for drugs used to treat COVID-19 |
|
| 1026 |
[GO] |
2020―Aug―14 |
Proton pump inhibitors increase risk of COVID-19 |
|
| 1027 |
[GO] |
2020―Aug―14 |
Health Canada approves first drug for treatment of COVID-19 |
|
| 1028 |
[GO] |
2020―Jul―24 |
Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients |
|
| 1029 |
[GO] |
2020―Jul―17 |
Meta-analysis: RAAS inhibitors and COVID-19 positivity and/or mortality |
|
| 1030 |
[GO] |
2020―Jun―26 |
New potential interaction with emergency COVID-19 medicine remdesivir |
|
| 1031 |
[GO] |
2020―Jun―12 |
Benefit-risk assessment for remdesivir in COVID-19 |
|
| 1032 |
[GO] |
2020―Jun―12 |
Risks of chloroquine or hydroxychloroquine use for COVID-19 |
|
| 1033 |
[GO] |
2020―Jun―05 |
COVID-19 pregnancy prevention guidance on teratogenic drugs |
|
| 1034 |
[GO] |
2020―Jun―05 |
UK's MHRA publishes guidance for valproate PPP during pandemic |
|
| 1035 |
[GO] |
2020―Mai―29 |
Chloroquine and hydroxychloroquine increase risk of death in COVID-19 |
|
| 1036 |
[GO] |
2020―Mai―29 |
Serious cardiac AEs with hydroxychloroquine during COVID-19 pandemic |
|
| 1037 |
[GO] |
2020―Mai―29 |
Cardiac adverse reactions with off-label Covid-19 treatments |
|
| 1038 |
[GO] |
2020―Mai―23 |
US guidance issued for postmarketing AE reporting during pandemic |
|
| 1039 |
[GO] |
2020―Mai―18 |
International Society of Pharmacovigilance: COVID-19 role |
|
| 1040 |
[GO] |
2020―Mai―18 |
MHRA COVID-19 website for reporting ADRs and incidents |
|
| 1041 |
[GO] |
2020―Mai―18 |
Risk of Covid-19 with renin-angiotensin-aldosterone system medications |
|
| 1042 |
[GO] |
2020―Mai―11 |
Evaluation of potential therapies for COVID-19 global pandemic |
|
| 1043 |
[GO] |
2020―Mai―11 |
Demand for potentially hazardous COVID-19 treatments |
|
| 1044 |
[GO] |
2020―Mai―11 |
UMC: use appropriate COVID-19-related terms for ICSRs |
|
| 1045 |
[GO] |
2020―Mai―04 |
ACEI inhibitors and ARBs do not increase severity of COVID-19 |
|
| 1046 |
[GO] |
2020―Mai―04 |
Safety concerns with higher dosage chloroquine in COVID-19 patients |
|
| 1047 |
[GO] |
2020―Mai―04 |
High incidence of ADRs in COVID-19 patients in China |
|
| 1048 |
[GO] |
2020―Mai―04 |
Antimalarial use in COVID-19 patients requires close monitoring |
|
| 1049 |
[GO] |
2020―Apr―20 |
EMA: continue use of ACE inhibitors, sartans during COVID-19 pandemic |
|
| 1050 |
[GO] |
2020―Apr―06 |
Regulatory agencies issue advice on use of NSAIDs for COVID-19 |
|
